[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5967
1. Sinigaglia R, Gigante C, Bisinella G, Varotto S, Zanesco L, Turra S: Musculoskeletal manifestations in pediatric acute leukemia. J Pediatr Orthop; 2008 Jan-Feb;28(1):20-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Musculoskeletal manifestations in pediatric acute leukemia.
  • BACKGROUND: In children, acute leukemia (AL) at presentation can mimic several orthopaedic pathologies, so that a variable delay of the correct diagnosis is often reported.
  • METHODS: To define more clearly the clinical and radiological musculoskeletal manifestations of leukemia in children, 122 affected children referred from 1984 to 1999 to our Pediatric Onco-Hematologic Clinic were retrospectively reviewed.
  • One hundred two (83.6%) had acute lymphoblastic leukemia, 20 (16.4%) had acute myeloid leukemia.
  • At presentation, 40.2% of children had at least 1 radiographic abnormality.
  • Radiographic abnormalities (P = 0.400), type of leukemia (P = 0.291), sex (P = 0.245), and white blood cell count at presentation (P = 0.877) were not prognostic factors.
  • Accurate history, general physical examination, and complete blood cell count tests should address the suspicion, which is confirmed by a peripheral and/or iliac crest bone marrow biopsy.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Musculoskeletal Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18157042.001).
  • [ISSN] 0271-6798
  • [Journal-full-title] Journal of pediatric orthopedics
  • [ISO-abbreviation] J Pediatr Orthop
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM, Wong RM, Negrin RS, Blume KG, Forman SJ: Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood; 2008 Aug 1;112(3):903-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen.
  • Allogeneic hematopoietic cell transplantation (HCT) is the only known curative modality for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL).
  • By univariate analysis, factors affecting event-free and overall survival were white blood cell count at diagnosis (< 30 x 10(9)/L vs > 30 x 10(9)/L) and disease status (CR1 vs > CR1).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2005 Nov;36(10):867-72 [16113659.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2791-3 [17119111.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2563-72 [18156492.001]
  • [Cites] Leukemia. 1999 Dec;13(12):2053-8 [10602428.001]
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):263-73 [10674898.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3702-9 [10845900.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] Blood. 2002 Aug 1;100(3):761-7 [12130483.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2357-66 [12239143.001]
  • [Cites] Semin Hematol. 2002 Oct;39(4 Suppl 3):32-7 [12447850.001]
  • [Cites] Br J Haematol. 2003 Jan;120(1):145-53 [12492591.001]
  • [Cites] Bone Marrow Transplant. 2003 May;31(10):909-18 [12748668.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 Aug;7(8):1109-15 [7028698.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Nov;9(11):1607-11 [6358154.001]
  • [Cites] Blood. 1992 Jun 1;79(11):3067-70 [1586748.001]
  • [Cites] Blood. 1993 Nov 1;82(9):2920-8 [8219241.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1672-9 [8068956.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1410-4 [9269758.001]
  • [Cites] Biol Blood Marrow Transplant. 1997 Dec;3(6):324-30 [9502300.001]
  • [Cites] Blood. 2005 May 1;105(9):3449-57 [15657178.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1509-16 [16034462.001]
  • [Cites] Blood. 1987 Apr;69(4):1015-20 [3548841.001]
  • [Cites] Blood. 1987 Aug;70(2):587-8 [3300815.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • (PMID = 18519812.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / P01 CA049605; United States / NCI NIH HHS / CA / P01-CA 30206; United States / NCI NIH HHS / CA / P01-CA 49605
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 6PLQ3CP4P3 / Etoposide; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ PMC2481551
  •  go-up   go-down


3. Friedman AD, Cook JR, Scharpf J: Precursor T-cell acute lymphoblastic lymphoma presenting as a tongue mass. J Otolaryngol Head Neck Surg; 2009 Feb;38(1):E16-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor T-cell acute lymphoblastic lymphoma presenting as a tongue mass.
  • [MeSH-major] Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Tongue Neoplasms / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19344598.001).
  • [ISSN] 1916-0216
  • [Journal-full-title] Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  • [ISO-abbreviation] J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Indraccolo S, Minuzzo S, Masiero M, Amadori A: Ligand-driven activation of the notch pathway in T-ALL and solid tumors: why Not(ch)? Cell Cycle; 2010 Jan 1;9(1):80-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Notch pathway is an evolutionally conserved cell-cell interaction signalling system involved in several key aspects of cell life, ranging from differentiation and proliferation to apoptosis.
  • The clearest example of oncogenic Notch signalling is observed in T acute lymphoblastic leukemia (T-ALL), an aggressive neoplasm of immature T-cells, due to genetic alterations leading to ligand-independent increased Notch1 receptor signalling.
  • In solid tumors, however, extrinsic regulation through canonical cell-cell interactions appears to drive activation of the pathway.
  • [MeSH-major] Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Receptors, Notch / metabolism
  • [MeSH-minor] Animals. Humans. Intracellular Signaling Peptides and Proteins. Leukemia / metabolism. Membrane Proteins / metabolism. Models, Biological. Neovascularization, Pathologic / metabolism. Signal Transduction / genetics. Signal Transduction / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20016278.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Receptors, Notch; 0 / delta protein
  •  go-up   go-down


5. Aljurf M, Zaidi SZ: Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies. Biol Blood Marrow Transplant; 2005 Oct;11(10):739-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies.
  • Adult T-cell lymphoblastic lymphoma is a relatively rare aggressive type of non-Hodgkin lymphoma with frequent involvement of extranodal sites.
  • The collective experience in the management of adult T-cell lymphoblastic lymphoma suggests a good outcome for patients with no adverse prognostic factors who are treated with an acute lymphocytic leukemia-like treatment strategy.
  • Patients with adverse prognostic features should be considered for more aggressive therapy-specifically, high-dose chemotherapy and hematopoietic stem cell transplantation.
  • This article will attempt to review the current status of chemotherapy treatment programs and the relative merits of the different hematopoietic stem cell transplantation programs in this disease, particularly in relation to the pathologic and clinical features that correlate with disease prognosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16182175.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 114
  •  go-up   go-down


6. Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M: Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant; 2008 May;14(5):568-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
  • We retrospectively evaluated the outcomes of 37 adult patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT) conditioned with medium-dose VP-16 (VP, 30 mg/kg), cyclophosphamide (CY, 120 mg/kg), and fractionated total-body irradiation (TBI, 12 Gy) (medium-dose VP/CY/TBI).
  • [MeSH-major] Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410899.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


7. Inukai T, Akahane K, Nemoto A, Kuroda I, Noguchi S, Hirose K, Honna H, Goi K, Kondo T, Iwasa S, Murata S, Kato R, Nakazawa S, Sugita K: Revision of the cytological diagnosis of CNS relapse into aseptic meningitis in a patient with TEL-AML1+ acute lymphoblastic leukaemia by FISH analysis of mononuclear cells in cerebrospinal fluid. Histopathology; 2007 Jun;50(7):947-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revision of the cytological diagnosis of CNS relapse into aseptic meningitis in a patient with TEL-AML1+ acute lymphoblastic leukaemia by FISH analysis of mononuclear cells in cerebrospinal fluid.
  • [MeSH-major] Diagnostic Errors. In Situ Hybridization, Fluorescence / methods. Leukocytes, Mononuclear / pathology. Meningitis, Aseptic / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17543087.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


8. Mostert S, Sitaresmi MN, Gundy CM, Janes V, Sutaryo, Veerman AJ: Comparing childhood leukaemia treatment before and after the introduction of a parental education programme in Indonesia. Arch Dis Child; 2010 Jan;95(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparing childhood leukaemia treatment before and after the introduction of a parental education programme in Indonesia.
  • SETTING: Previously, treatment and the results of treatment for childhood acute lymphoblastic leukaemia (ALL) in Indonesia differed significantly between poor and prosperous patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Health Education / organization & administration. Parents / education. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679573.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


9. Kato M, Kikuchi A, Oshima K, Yamamoto S, Mochizuki S, Arai K, Hanada R: [Pediatric acute lymphoblastic leukemia initially presenting with bone marrow necrosis]. Rinsho Ketsueki; 2007 Feb;48(2):140-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pediatric acute lymphoblastic leukemia initially presenting with bone marrow necrosis].
  • We report on a case of pediatric acute lymphoblastic leukemia presenting with massive bone marrow necrosis.
  • [MeSH-major] Bone Marrow / pathology. Bone Marrow Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis


10. Jiang JG, Roman E, Nandula SV, Murty VV, Bhagat G, Alobeid B: Congenital MLL-positive B-cell acute lymphoblastic leukemia (B-ALL) switched lineage at relapse to acute myelocytic leukemia (AML) with persistent t(4;11) and t(1;6) translocations and JH gene rearrangement. Leuk Lymphoma; 2005 Aug;46(8):1223-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital MLL-positive B-cell acute lymphoblastic leukemia (B-ALL) switched lineage at relapse to acute myelocytic leukemia (AML) with persistent t(4;11) and t(1;6) translocations and JH gene rearrangement.
  • Congenital acute leukemia is a rare form of childhood leukemia, in which lineage conversion at relapse is very rarely reported.
  • Here we describe a case of congenital B-cell acute lymphoblastic leukemia (B-ALL) with t(4;11) and t(1;6) translocations, which at relapse underwent a switch to monocytic lineage with persistence of the original cytogenetic translocations and clonal rearrangement of the JH gene.
  • Similar to the other described cases of congenital acute leukemia with lineage conversion, our case had a MLL gene rearrangement and followed an aggressive clinical course.
  • [MeSH-major] Burkitt Lymphoma / genetics. Leukemia, Myeloid, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Cell Lineage. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 4 / genetics. Chromosomes, Human, Pair 6 / genetics. Cytogenetic Analysis. Disease Progression. Fatal Outcome. Female. Histone-Lysine N-Methyltransferase. Humans. Immunoglobulin Heavy Chains / genetics. Immunoglobulin J-Chains / genetics. Immunophenotyping. Infant, Newborn. Prognosis. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085566.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin J-Chains; 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


11. Hiissa J, Elo LL, Huhtinen K, Perheentupa A, Poutanen M, Aittokallio T: Resampling reveals sample-level differential expression in clinical genome-wide studies. OMICS; 2009 Oct;13(5):381-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When applied to a public leukemia microarray study, the procedure could accurately reveal hidden subgroup structures associated with underlying genotypic abnormalities.
  • [MeSH-minor] Algorithms. Cluster Analysis. Databases, Genetic. Endometriosis / genetics. Female. Gene Expression Regulation. Humans. Models, Statistical. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19663710.001).
  • [ISSN] 1557-8100
  • [Journal-full-title] Omics : a journal of integrative biology
  • [ISO-abbreviation] OMICS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Volc SM, Almeida MT, Abadi MD, Cornacchioni AL, Odone Filho V, Cristofani LM: Measles and rubella antibody status in children after treatment for acute lymphoblastic leukemia. J Pediatr (Rio J); 2006 Nov-Dec;82(6):481-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measles and rubella antibody status in children after treatment for acute lymphoblastic leukemia.
  • OBJECTIVE: To assess the vaccination history and the status of vaccine-induced protection from measles and rubella in children after treatment for acute lymphoblastic leukemia.
  • METHODS: Measles and rubella immunological status was assessed by the ELISA technique for 22 children previously treated for acute lymphoblastic leukemia.
  • We recommend that a measles booster be given after the completion of treatment for acute lymphoblastic leukemia and that rubella immunity status should be assessed at this point, with revaccination performed when necessary.
  • [MeSH-major] Measles / immunology. Measles Vaccine / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Rubella / immunology. Rubella Vaccine / immunology


13. Snyder DS, Stein AS, O'Donnell MR, Gaal K, Slovak ML, Forman SJ: Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature. Am J Hematol; 2005 Jan;78(1):74-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature.
  • The most common hematologic SMNs are myelodysplasia (MDS) and acute myelogenous leukemia (AML).
  • Acute lymphoblastic leukemia (ALL) is uncommon in this patient population, and Philadelphia chromosome positive (Ph+) ALL in particular, is rare.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bone Neoplasms / drug therapy. Bone Neoplasms / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Radiation Injuries / complications. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / radiotherapy


14. T'sas F, Brenner C, Mauen S, Putmans P, Monté D, Van Lint C, Moser M, Baert JL, de Launoit Y: Expression of the Ets transcription factor Erm is regulated through a conventional PKC signaling pathway in the Molt4 lymphoblastic cell line. FEBS Lett; 2005 Jan 3;579(1):66-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the Ets transcription factor Erm is regulated through a conventional PKC signaling pathway in the Molt4 lymphoblastic cell line.
  • Here, we show that in the human Molt4 lymphoblastic cell line, the erm gene expression is regulated by the conventional PKC (cPKC) pathway.
  • [MeSH-minor] Cell Line, Tumor. Dactinomycin / pharmacology. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma. RNA, Messenger / analysis. RNA, Messenger / metabolism. Sequence Deletion / genetics. Transcription, Genetic / drug effects. Transcription, Genetic / physiology. Up-Regulation

  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620692.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / ETV5 protein, human; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / transcription factor PEA3; 1CC1JFE158 / Dactinomycin; 56937-68-9 / phorbolol myristate acetate; EC 2.7.11.13 / Protein Kinase C; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


15. Thompson PA, Murry DJ, Rosner GL, Lunagomez S, Blaney SM, Berg SL, Camitta BM, Dreyer ZE, Bomgaars LR: Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol; 2007 May;59(6):847-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia.
  • PURPOSE: We performed a pharmacokinetic evaluation of methotrexate (MTX) in infants with acute lymphoblastic leukemia enrolled on the Pediatric Oncology Group (POG) 9407 Infant Leukemia Study to evaluate the effects of age on MTX pharmacokinetics and pharmacodynamics.
  • [MeSH-major] Methotrexate / pharmacokinetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17136402.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 30969
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


16. Sikora P, Borzecka H, Kołłataj B, Majewski M, Wieczorkiewicz-Płaza A, Zajaczkowska M: [The diagnosis of familial hypomagnesemia with hypercalciuria and nephrocalcinosis in a girl with acute lymphoblastic leukemia--case report]. Pol Merkur Lekarski; 2006 Apr;20(118):430-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The diagnosis of familial hypomagnesemia with hypercalciuria and nephrocalcinosis in a girl with acute lymphoblastic leukemia--case report].
  • We present 16-year old girl in whom symptoms of FHHNC were accidentally recognized during therapy of acute lymphoblastic leukemia.
  • To the best of our knowledge, this is the first report of FHHNC associated with acute lymphoblastic leukemia.
  • [MeSH-major] Hypophosphatemia, Familial / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Nephrocalcinosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886568.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


17. Chisholm JC: Reimmunization after therapy for childhood cancer. Clin Infect Dis; 2007 Mar 1;44(5):643-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Vaccines / immunology

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Immunization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Infect Dis. 2007 Mar 1;44(5):625-34 [17278051.001]
  • [CommentOn] Clin Infect Dis. 2007 Mar 1;44(5):635-42 [17278052.001]
  • (PMID = 17278053.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Vaccines
  •  go-up   go-down


18. Chen BA, Zhang F, Wang Y, Zheng WL, Du J, Gao C, Ding JH, Sun YY, Cheng J, Wang J, Zhao G, Chen NN, Lu ZH: [Quantitative microarray-based DNA methylation analysis of E-cadherin gene promoter in acute leukemia]. Zhonghua Zhong Liu Za Zhi; 2007 Jan;29(1):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Quantitative microarray-based DNA methylation analysis of E-cadherin gene promoter in acute leukemia].
  • OBJECTIVE: To quantitatively detect the methylation of E-cadherin gene 5'-CpG islands in acute leukemia by microarray-based DNA analysis and to briefly discuss the role of microarry for detection of methylation in tumors.
  • Five sets of oligonucleotide probes were designed to fabricate a DNA microarray to detect the methylation changes of E-cadherin gene CpG islands in acute leukemia.
  • RESULTS: Microarray assay was successfully used to quantitatively detect methylation changes of E-cadherin gene in 5 acute leukemia samples.
  • CONCLUSION: Microarray assay may be applied as an useful tool for mapping methylation changes in multiple CpG loci and for leukemia research.
  • [MeSH-major] Cadherins / genetics. DNA Methylation. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575692.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


19. Ning F, Cai SJ, Zhang TJ, Liu XX, Zhang YM: [Expression of nm23 H(1) gene in childhood acute lymphoblastic leukemia and the relationship between nm23 H(1) expression and immunophenotype]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Nov;11(11):881-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of nm23 H(1) gene in childhood acute lymphoblastic leukemia and the relationship between nm23 H(1) expression and immunophenotype].
  • OBJECTIVE: To study the expression of nm23-H(1) gene in children with acute lymphoblastic leukemia (ALL) and the relationship between nm23-H(1) expression and immunophenotype.
  • [MeSH-major] NM23 Nucleoside Diphosphate Kinases / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


20. Truffinet V, Vincent C, Donnard M, Bordessoule D, Turlure P, Trimoreau F, Denizot Y: No effect of platelet-activating factor on the proliferation and apoptosis of immature forms of leukemic blasts. Leuk Res; 2007 Dec;31(12):1766-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Apoptosis. Cell Proliferation. Leukemia / pathology. Platelet Activating Factor / physiology
  • [MeSH-minor] Blast Crisis / pathology. Humans. Leukemia, Myeloid, Acute. Leukocytes / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350684.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Platelet Activating Factor
  •  go-up   go-down


21. Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P: Dasatinib. Nat Rev Drug Discov; 2006 Sep;5(9):717-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Administration, Oral. Adult. Clinical Trials as Topic. Dasatinib. Drug Approval / methods. Guideline Adherence / standards. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Molecular Structure. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001803.001).
  • [ISSN] 1474-1776
  • [Journal-full-title] Nature reviews. Drug discovery
  • [ISO-abbreviation] Nat Rev Drug Discov
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; RBZ1571X5H / Dasatinib
  •  go-up   go-down


22. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell; 2005 Feb;7(2):129-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
  • Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Fusion Proteins, bcr-abl / antagonists & inhibitors. Fusion Proteins, bcr-abl / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / chemistry. Pyrimidines / pharmacology
  • [MeSH-minor] Animals. Benzamides. Bone Marrow Cells / cytology. Cell Line. Cell Line, Tumor. Cell Survival. Crystallography, X-Ray. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Hematopoietic Stem Cells / cytology. Imatinib Mesylate. Inhibitory Concentration 50. Mice. Models, Biological. Models, Chemical. Mutation. Mycoplasma / metabolism. Phosphorylation. Piperazines / pharmacology. Retroviridae / genetics. Time Factors

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Cell. 2005 Apr;7(4):399. Mohammed, Azam [corrected to Azam, Mohammad]
  • (PMID = 15710326.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA36167; United States / NCI NIH HHS / CA / CA66996; United States / NCI NIH HHS / CA / CA86991; United States / NIDDK NIH HHS / DK / DK50654
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


23. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA: Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer; 2008 Jun;50(6):1198-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dasatinib, a dual inhibitor of the src and abl tyrosine kinases, was recently approved by the Federal Drug Administration for the treatment of imatinib mesylate-resistant chronic myeloid leukemia.
  • PROCEDURES: Dasatinib was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro panel at concentrations ranging from 0.1 nM to 1.0 microM and was tested in vivo at a dose of 50 mg/kg administered orally twice daily 5 days per week for 4 weeks for the solid tumor xenografts and once daily for the acute lymphoblastic leukemia (ALL) xenografts.
  • RESULTS: Dasatinib was selectively active against the cell lines of the PPTP in vitro panel, reaching an IC(50) in 6 of the 22 lines.
  • Dasatinib had limited in vivo activity against the PPTP solid tumor xenografts, but was highly active against a Ph(+) ALL xenograft and also had anti-leukemia activity against two other xenografts.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17914733.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CM / N01 CM042216; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CM / N01-CM-42216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; RBZ1571X5H / Dasatinib
  •  go-up   go-down


24. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, Litzow MR, Luger SM, McMillan AK, Mansour MR, Rowe JM, Tallman MS, Lazarus HM: T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood; 2009 Dec 10;114(25):5136-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
  • The biology and outcome of adult T-cell acute lymphoblastic leukemia are poorly understood.
  • This study provides a baseline for trials of new drugs, such as nelarabine, and may allow risk-adapted therapy in patients with poor-prognosis T-cell ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation / methods. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 2000 Sep 21;243(1-2):59-75 [10986407.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4352-6 [19635999.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Apr;16(2):245-99, v [12094473.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jan;127(1):42-8 [12521365.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Dec;16(4):671-83 [14592650.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Blut. 1990 Jan;60(1):48-51 [2297585.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Mar;52(1):79-84 [2009514.001]
  • [Cites] Leukemia. 1996 Nov;10(11):1832-3 [8892689.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3931-9 [10339502.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3028-37 [15256423.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Blood. 2006 Jan 15;107(2):473-9 [16179376.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(11):989-95 [16633362.001]
  • [Cites] Blood. 2006 Jul 15;108(2):465-72 [16556888.001]
  • [Cites] Blood. 2007 Feb 1;109(3):910-5 [17023577.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Leukemia. 2007 Apr;21(4):622-6 [17301806.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Nature. 2008 Apr 10;452(7188):764-7 [18401411.001]
  • [Cites] Br J Haematol. 2008 Oct;143(2):153-68 [18691165.001]
  • [Cites] Blood. 2009 Jan 1;113(1):100-7 [18838613.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [Cites] Haematologica. 2001 Jul;86(7):675-92 [11454522.001]
  • (PMID = 19828704.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856; United Kingdom / Medical Research Council / / G8223452; United Kingdom / Medical Research Council / / G0500389; United States / NCI NIH HHS / CA / R01CA120196; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / R01 CA120196-03
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Other-IDs] NLM/ PMC2792210
  •  go-up   go-down


25. Xi YM, Shi XE, Li P, Zhang H, Li M, Liu B, Yao XJ, Xu JW: [Relationship between polymorphisms of myeloperoxidase gene and susceptibility of acute leukemia in Chinese Gansu population]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec;18(6):1431-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between polymorphisms of myeloperoxidase gene and susceptibility of acute leukemia in Chinese Gansu population].
  • This study was aimed to explore the relationship between gene polymorphisms of myeloperoxidase (MPO) and the susceptibility of acute leukemia in Chinese Gansu population.
  • G463A mutation of mpo gene was analyzed by polymerase chain reaction-ligase detection reaction (PCR-LDR) in 100 normal individuals (control group) and 100 patients with acute leukemia (AL group).
  • AML risk (95%CI = 0.157 - 0.546, p < 0.01) in the controls was decreased by 0.346-fold compared with the individual with gg genotype, however, the acute lymphoblastic leukemia (ALL) showed no significant difference from control group in the incidence of the allele a genotype and ga/aa genotype of mpo gene.
  • It is concluded that mpo gene polymorphism is associated with susceptibility of acute myeloid leukemia in Chinese Gansu population.
  • The risk of AML decreases in the persons carrying a allele, but mpo gene polymorphism is not associated with susceptibility of acute lymphoblastic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176345.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


26. Wang JD, Chang TK, Shu SG: Lymphoblastic lymphoma arising at the insulin injection sites in a child with type 1 diabetes mellitus. J Pediatr; 2010 Dec;157(6):1043-1043.e1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoblastic lymphoma arising at the insulin injection sites in a child with type 1 diabetes mellitus.
  • [MeSH-major] Diabetes Mellitus, Type 1 / drug therapy. Insulin / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Soft Tissue Neoplasms / etiology


27. Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R, Cao X, Varambally S, Thomas DG, Giordano TJ, Beer DG, Palanisamy N, Sartor MA, Omenn GS, Chinnaiyan AM: An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol; 2009 Nov;27(11):1005-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By analyzing lung cancer transcriptome sequencing and genomic data, we identified a novel R3HDM2-NFE2 fusion in the H1792 cell line.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Res. 2002 Apr;12(4):656-64 [11932250.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12353-8 [19592507.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3814-22 [15172988.001]
  • [Cites] Biostatistics. 2004 Oct;5(4):557-72 [15475419.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Jul 16;224(2):289-96 [8702385.001]
  • [Cites] Nat Genet. 1997 Apr;15 Spec No:417-74 [9140409.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-72 [16381955.001]
  • [Cites] Neurogenetics. 2006 May;7(2):67-80 [16572319.001]
  • [Cites] FEBS Lett. 2006 Dec 22;580(30):6769-76 [17141222.001]
  • [Cites] Neoplasia. 2007 Feb;9(2):166-80 [17356713.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Genome Biol. 2007;8(3):R39 [17367534.001]
  • [Cites] Nucleic Acids Res. 2007 Jul;35(Web Server issue):W625-32 [17586824.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):513-29 [17639064.001]
  • [Cites] J Cell Biochem. 2007 Aug 15;101(6):1492-504 [17295210.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] PLoS Comput Biol. 2008 Apr;4(4):e1000051 [18404202.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Nat Rev Cancer. 2008 Jul;8(7):497-511 [18563191.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1320-34 [18528425.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3038-50 [18704194.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D767-72 [18988627.001]
  • [Cites] Oncogene. 2008 Dec 11;27(58):7274-84 [18806826.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D277-80 [14681412.001]
  • (PMID = 19881495.001).
  • [ISSN] 1546-1696
  • [Journal-full-title] Nature biotechnology
  • [ISO-abbreviation] Nat. Biotechnol.
  • [Language] ENG
  • [Databank-accession-numbers] GENBANK/ GU068583
  • [Grant] United States / NIDA NIH HHS / DA / U54 DA021519-05; United States / NCI NIH HHS / CA / CA009676-18; United States / NCI NIH HHS / CA / CA111275-06; United States / NCI NIH HHS / CA / U01 CA111275-06; United States / NCI NIH HHS / CA / T32 CA009676; United States / NIDA NIH HHS / DA / U54 DA021519; United States / NCI NIH HHS / CA / U01 CA111275
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS285794; NLM/ PMC3086882
  •  go-up   go-down


28. Chen TY, Chen JS, Su WC, Wu MS, Tsao CJ: Expression of DNA repair gene Ku80 in lymphoid neoplasm. Eur J Haematol; 2005 Jun;74(6):481-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Competitive reverse transcription-polymerase chain reaction assays were performed and the expression levels of Ku80 were measured in normal peripheral blood mononuclear cells (n = 9) and malignant cells from 25 patients with acute lymphoblastic leukemia (ALL) (14 children, 11 adults), and chronic lymphoproliferative disorders (n = 6).
  • RESULTS: No mutation or Ku80 variant at the RNA level was seen in any patient samples or in the Raji or CCRF-CEM cell lines.
  • The amount of Ku80 expression in ALL was moderately correlated with peripheral white blood cell counts, but not with Ki67 labeling index.
  • [MeSH-major] Antigens, Nuclear / biosynthesis. DNA Repair / genetics. DNA-Binding Proteins / biosynthesis. Gene Expression Regulation, Leukemic. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Cell Line, Tumor. Child. Child, Preschool. Humans. Infant. Ki-67 Antigen / biosynthesis. Ki-67 Antigen / genetics. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Prognosis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876251.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Ku autoantigen; 0 / RNA, Messenger
  •  go-up   go-down


29. Deneberg S, Lerner R, Ljungman P, Ringden O, Hägglund H: Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease: implications for its use? Med Oncol; 2007;24(3):354-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In acute lymphatic leukaemia (ALL) treated with allogenic stem cell transplantation limited chronic graft versus host disease (cGVHD) is associated with a higher 5 year disease free survival.
  • This indicates an important graft-versus-leukemia (GVL) effect, although this effect is less pronounced in ALL than in other malignancies.
  • B-cell depletion using Rituximab is a treatment option in therapy refractory cGVHD that has been used successfully in a limited number of patients with an approximate response rate of 70%.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Graft vs Host Disease / prevention & control. Immunologic Factors / therapeutic use. Neoplasm Recurrence, Local / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Fatal Outcome. Humans. Male. Rituximab. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Oct 15;104(8):2603-6 [15251978.001]
  • [Cites] Curr Opin Oncol. 1998 Nov;10(6):548-51 [9818234.001]
  • [Cites] Leukemia. 2006 Jan;20(1):172-3 [16239908.001]
  • [Cites] Leukemia. 1997 May;11 Suppl 4:S15-7 [9179275.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Aug;9(8):505-11 [12931119.001]
  • [Cites] Curr Opin Hematol. 2006 Nov;13(6):426-35 [17053454.001]
  • [Cites] Blood. 2006 Jul 15;108(2):756-62 [16551963.001]
  • [Cites] Bone Marrow Transplant. 1998 Jan;21(2):153-8 [9489632.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Mar;10(3):195-203 [14993885.001]
  • [Cites] Mayo Clin Proc. 2006 Mar;81(3):377-84 [16529141.001]
  • [Cites] Bone Marrow Transplant. 2005 Jun;35(12):1141-8 [15834433.001]
  • (PMID = 17873314.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


30. Marino S, Verzegnassi F, Tamaro P, Stocco G, Bartoli F, Decorti G, Rabusin M: Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response. Pediatr Blood Cancer; 2009 Dec;53(6):984-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response.
  • BACKGROUND: Glucocorticoids (GCs) play a fundamental role in the treatment of pediatric acute lymphoblastic leukemia (ALL), but therapy with these agents often results in a number of severe side effects.
  • [MeSH-major] Glucocorticoids / administration & dosage. Glutathione Transferase / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621425.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


31. Fadzilah MN, Faizatul LJ, Hasibah MS, Sam IC, Bador MK, Gan GG, Abubakar S: Anaerobiospirillum succiniciproducens bacteraemia in a patient with acute lymphoblastic leukaemia. J Med Microbiol; 2009 Jan;58(Pt 1):142-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaerobiospirillum succiniciproducens bacteraemia in a patient with acute lymphoblastic leukaemia.
  • A 17-year-old man with acute lymphoblastic leukaemia had fever and diarrhoea during a febrile neutropenic episode.
  • [MeSH-major] Anaerobiospirillum / isolation & purification. Bacteremia / microbiology. Gram-Negative Bacterial Infections / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074667.001).
  • [ISSN] 0022-2615
  • [Journal-full-title] Journal of medical microbiology
  • [ISO-abbreviation] J. Med. Microbiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


32. Goodman M, Dana Flanders W: Study design options in evaluating gene-environment interactions: practical considerations for a planned case-control study of pediatric leukemia. Pediatr Blood Cancer; 2007 Apr;48(4):375-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study design options in evaluating gene-environment interactions: practical considerations for a planned case-control study of pediatric leukemia.
  • BACKGROUND: We compare methodological approaches for evaluating gene-environment interaction using a planned study of pediatric leukemia as a practical example.
  • Using the leukemia study example, we calculated sample sizes required to detect and odds ratio (OR) of 2.0 for E alone, an OR of 10 for G alone and an interaction G x E of 3.
  • [MeSH-major] Case-Control Studies. Cocarcinogenesis. Genes, Neoplasm. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Research Design / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2007 Apr;48(4):373-4 [16917907.001]
  • (PMID = 16874764.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


33. Kubicka M, Soszynska K, Mucha B, Rafinska B, Kolodziej B, Haus O, Styczynski J: Unusual profiles of pediatric acute lymphoblastic leukemia with MLL gene rearrangement. Leuk Lymphoma; 2007 Oct;48(10):2083-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual profiles of pediatric acute lymphoblastic leukemia with MLL gene rearrangement.
  • [MeSH-major] Gene Rearrangement. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917979.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


34. Wang C, Camfield CS, Fernandez CV, Hurley T, Campbell K: Successful neurological outcome of a child with classical phenylketonuria and acute lymphoblastic leukemia: a 7-year follow-up. Am J Med Genet A; 2007 Dec 15;143A(24):3324-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful neurological outcome of a child with classical phenylketonuria and acute lymphoblastic leukemia: a 7-year follow-up.
  • We report on the medical management and outcome of a child with classical phenylketonuria (PKU) who developed acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Phenylketonurias / complications. Phenylketonurias / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Phenylketonuria.
  • MedlinePlus Health Information. consumer health - Phenylketonuria.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17480007.001).
  • [ISSN] 1552-4833
  • [Journal-full-title] American journal of medical genetics. Part A
  • [ISO-abbreviation] Am. J. Med. Genet. A
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47E5O17Y3R / Phenylalanine
  •  go-up   go-down


35. Winter SS, Jiang Z, Khawaja HM, Griffin T, Devidas M, Asselin BL, Larson RS, Children's Oncology Group: Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood; 2007 Sep 1;110(5):1429-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group.
  • The clinical and cytogenetic features associated with T-cell acute lymphoblastic leukemia (T-ALL) are not predictive of early treatment failure.
  • Seven genes were similarly upregulated in both the genomic classifier for IF patients and T-ALL cell lines having acquired resistance to neoplastic agents, identifying potential target genes for further study in drug resistance.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 Jun 15;332(24):1618-30 [7753142.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4288-95 [8943865.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2222-30 [9196134.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):291-9 [15665306.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1933-8 [15671173.001]
  • [Cites] Clin Pharmacokinet. 2005;44(4):367-93 [15828851.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1270-8 [9552025.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] Biochem J. 1999 Aug 15;342 ( Pt 1):163-70 [10432313.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] J Immunol. 2004 Nov 15;173(10):6151-60 [15528352.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8987-93 [15604263.001]
  • [Cites] Blood. 2005 Jan 15;105(2):821-6 [15388585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13264-9 [10557309.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] BMC Genomics. 2005;6:59 [15854232.001]
  • [Cites] Eur J Cancer. 2005 Jun;41(9):1300-3 [15869873.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):55-65 [16369572.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):179-86 [16007607.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):60-4 [16377171.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):570-8 [16365862.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):130-40 [16358311.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1400-7 [16728981.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1385-92 [16761018.001]
  • [Cites] Blood. 2006 Aug 1;108(3):986-92 [16621969.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] Future Oncol. 2006 Aug;2(4):441-8 [16922610.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5329-35 [17000665.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1226-32 [9242556.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):600-12 [9452280.001]
  • [Cites] Blood. 1998 Feb 1;91(3):735-46 [9446631.001]
  • [Cites] Int J Cancer. 1998 Mar 16;75(6):855-63 [9506530.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):920-30 [9508174.001]
  • [Cites] Leukemia. 1999 Nov;13(11):1696-707 [10557041.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Leukemia. 2000 May;14(5):792-5 [10803508.001]
  • [Cites] Blood. 2000 May 15;95(10):3199-203 [10807788.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2543-9 [11001909.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2394-403 [11160298.001]
  • [Cites] Biochem J. 2001 Jul 1;357(Pt 1):321-8 [11415466.001]
  • [Cites] Biochem J. 2001 Aug 15;358(Pt 1):59-67 [11485552.001]
  • [Cites] Jpn J Cancer Res. 2001 Aug;92(8):896-903 [11509123.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4386-93 [12036866.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1432-6 [12145681.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3118-30 [12374679.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1126-34 [12414341.001]
  • [Cites] Oncogene. 2003 Jan 16;22(2):308-13 [12527900.001]
  • [Cites] Leukemia. 2003 Jan;17(1):138-48 [12529671.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] J Immunol. 2003 May 1;170(9):4612-22 [12707339.001]
  • [Cites] J Histochem Cytochem. 2003 Jun;51(6):715-26 [12754283.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):396-405 [12800151.001]
  • [Cites] Blood. 2003 Jul 1;102(1):262-8 [12637319.001]
  • [Cites] Oncogene. 2003 Jul 10;22(28):4398-405 [12853976.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1842-8 [12750168.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3616-22 [14512392.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Oncologist. 2003;8(5):411-24 [14530494.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] Leukemia. 2004 Jan;18(1):63-71 [14603332.001]
  • [Cites] Nat Immunol. 2004 Feb;5(2):182-9 [14745445.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1909-11 [14604958.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2771-8 [14684422.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Hematology. 2004 Apr;9(2):91-105 [15203864.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):601-3 [15295054.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Clin Chem. 2004 Nov;50(11):1994-2002 [15364885.001]
  • [Cites] Blood. 1990 Jan 1;75(1):166-73 [1688495.001]
  • [ErratumIn] Blood. 2008 May 1;111(9):4830
  • (PMID = 17495134.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA29139; United States / NCI NIH HHS / CA / R21 CA098251; United States / NCI NIH HHS / CA / U10 CA98543-03-14305; United States / NCI NIH HHS / CA / R01 CA114589; United States / NCI NIH HHS / CA / U10 CA029139; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / R01 CA114589-01; United States / NCI NIH HHS / CA / R21 CA098251-01
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1975833
  •  go-up   go-down


36. Prebet T, Mozziconacci MJ, Sainty D, Arnoulet C, Lafage M, Dastugue N, Charbonnier A, Coso D, Gastaut JA, Blaise D, Vey N: Presence of a minor Philadelphia-positive clone in young adults with de novo T-cell ALL. Leuk Lymphoma; 2009 Mar;50(3):485-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of a minor Philadelphia-positive clone in young adults with de novo T-cell ALL.
  • [MeSH-major] Philadelphia Chromosome. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Clone Cells / pathology. Cytogenetic Analysis. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Polymerase Chain Reaction. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Mar;50(3):321-2 [19294558.001]
  • (PMID = 19197723.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


37. Downing JR, Mullighan CG: Tumor-specific genetic lesions and their influence on therapy in pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program; 2006;:118-22, 508
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-specific genetic lesions and their influence on therapy in pediatric acute lymphoblastic leukemia.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124049.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / P01 CA-71907-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


38. O'Connor SM, Boneva RS: Infectious etiologies of childhood leukemia: plausibility and challenges to proof. Environ Health Perspect; 2007 Jan;115(1):146-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious etiologies of childhood leukemia: plausibility and challenges to proof.
  • Infections as well as environmental exposures are proposed determinants of childhood acute lymphoblastic leukemia (ALL), particularly common precursor B-cell ALL (cALL).
  • Ideally, studies should document that particular infections precede leukemiA and induce malignant transformation.
  • Other challenges to proof include the likely time lag between infection and diagnosis, the ubiquity of many infections, the influence of age at infection, and the limitations in laboratory assays; small numbers of cases, inaccurate background leukemia rates, and difficulty tracking mobile populations further affect duster investigations.
  • [MeSH-major] Communicable Diseases / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • MedlinePlus Health Information. consumer health - Infectious Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):898-9 [10555765.001]
  • [Cites] Br J Cancer. 1997;75(11):1711-3 [9184193.001]
  • [Cites] Br J Cancer. 1997;76(12):1539-45 [9413937.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):677-8 [9484830.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):678 [9484831.001]
  • [Cites] Int J Cancer. 1998 Jun 19;79(3):273-7 [9645350.001]
  • [Cites] Cancer Causes Control. 1998 May;9(3):285-98 [9684709.001]
  • [Cites] Br J Cancer. 1998 Sep;78(5):561-5 [9744491.001]
  • [Cites] Lancet. 1998 Nov 21;352(9141):1707-8 [9853465.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):655-7 [10027345.001]
  • [Cites] Eur J Cancer. 1999 Jan;35(1):91-6 [10211094.001]
  • [Cites] Pediatrics. 1987 Jan;79(1):55-60 [3797171.001]
  • [Cites] Leukemia. 1988 Feb;2(2):120-5 [3278171.001]
  • [Cites] N Engl J Med. 1989 Mar 16;320(11):689-95 [2537928.001]
  • [Cites] Ann Intern Med. 1993 Mar 15;118(6):448-54 [8382459.001]
  • [Cites] Leukemia. 1993 Mar;7(3):349-60 [8445941.001]
  • [Cites] BMJ. 1993 Sep 25;307(6907):774 [8219951.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):1-5 [7819022.001]
  • [Cites] Lancet. 1995 Jul 22;346(8969):252-3 [7616826.001]
  • [Cites] Am J Public Health. 1995 Aug;85(8 Pt 1):1109-12 [7625505.001]
  • [Cites] Br J Cancer. 1997;75(3):457-63 [9020498.001]
  • [Cites] Lancet. 1997 Feb 1;349(9048):344-9 [9024390.001]
  • [Cites] J Immunother. 1997 Mar;20(2):89-100 [9087381.001]
  • [Cites] Am J Epidemiol. 2000 Dec 15;152(12):1136-44 [11130619.001]
  • [Cites] Leukemia. 2001 Mar;15(3):415-21 [11237065.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4004-9 [11274424.001]
  • [Cites] Cancer Causes Control. 2001 Aug;12(6):483-90 [11519756.001]
  • [Cites] Front Biosci. 2002 Jan 1;7:d268-74 [11779700.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1064-9 [11953850.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1419-24 [11986774.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):585-90 [10408870.001]
  • [Cites] Br J Cancer. 1999 Jan;79(1):30-3 [10408689.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1057-62 [10419898.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):439-44 [10448296.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1844-51 [10468308.001]
  • [Cites] Lancet. 1999 Aug 14;354(9178):532 [10470695.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):175-8 [10487630.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1866-72 [15520821.001]
  • [Cites] Int J Cancer. 2005 Jul 1;115(4):599-605 [15700307.001]
  • [Cites] BMJ. 2005 Jun 4;330(7503):1294 [15849205.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):747-55 [16084943.001]
  • [Cites] Pediatrics. 2005 Nov;116(5):e724-31 [16263987.001]
  • [Cites] J Autoimmun. 2005;25 Suppl:74-80 [16278064.001]
  • [Cites] Haematologica. 2006 Feb;91(2):240-3 [16461310.001]
  • [Cites] Emerg Infect Dis. 2006 Jul;12(7):1051-7 [16836820.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):234-40 [10638995.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1023-31 [10648418.001]
  • [Cites] Br J Haematol. 2000 Apr;109(1):64-70 [10848783.001]
  • [Cites] JAMA. 2000 Jul 12;284(2):205-9 [10889594.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1559-64 [11076669.001]
  • [Cites] Pediatr Blood Cancer. 2004 Apr;42(4):357-60 [14966833.001]
  • [Cites] Med Hypotheses. 2004;62(3):387-91 [14975509.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):336-61 [15129647.001]
  • [Cites] J Infect Dis. 2004 Jun 15;189(12):2271-81 [15181575.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1361-70 [15298959.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6341-8 [15322509.001]
  • [Cites] Br J Cancer. 2004 Aug 31;91(5):913-5 [15292925.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):243-63 [15491284.001]
  • [Cites] Br Med J. 1968 Dec 7;4(5631):604-8 [5247313.001]
  • [Cites] Md State Med J. 1969 Nov;18(11):73-7 passim [5352399.001]
  • [Cites] J Med. 1970;1(3):180-7 [4995531.001]
  • [Cites] J Natl Cancer Inst. 1982 Aug;69(2):333-7 [6287075.001]
  • [Cites] Am J Epidemiol. 1986 Oct;124(4):590-4 [3463201.001]
  • [Cites] Leuk Res. 2002 Jul;26(7):651-6 [12008082.001]
  • [Cites] Med Pediatr Oncol. 2002 Jun;38(6):391-7 [11984799.001]
  • [Cites] Paediatr Perinat Epidemiol. 2002 Apr;16(2):154-65 [12060313.001]
  • [Cites] Med Pediatr Oncol. 2003 Apr;40(4):219-23 [12555248.001]
  • [Cites] Am J Epidemiol. 2003 Aug 1;158(3):207-13 [12882942.001]
  • [Cites] Br J Haematol. 2003 Oct;123(1):60-5 [14510943.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Science. 2003 Oct 17;302(5644):415-9 [14564000.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):139-45 [14710221.001]
  • [Cites] Med Pediatr Oncol. 1999 Nov;33(5):441-3 [10531566.001]
  • (PMID = 17366835.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 86
  • [Other-IDs] NLM/ PMC1817664
  •  go-up   go-down


39. Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C, Picardi M, Specchia G, Mancini M, Cuneo A, Mecucci C, Martinelli G, Saglio G, Rotoli B, Mandelli F, Salvatore F, Foà R, GIMEMA group: Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia; 2005 Apr;19(4):628-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
  • Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has a dismal prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fusion Proteins, bcr-abl / genetics. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744351.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


40. Raetz EA, Perkins SL, Bhojwani D, Smock K, Philip M, Carroll WL, Min DJ: Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer; 2006 Aug;47(2):130-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
  • BACKGROUND: T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL) and are often thought to represent a spectrum of a single disease.
  • The malignant cells in T-ALL and T-LL are morphologically indistinguishable, and they share the expression of common cell surface antigens and cytogenetic characteristics.
  • CONCLUSIONS: Despite significant similarities between the malignant T-cell precursors, clear differences in the gene expression profiles were observed between T-ALL and T-LL implying underlying differences in the biology of the two entities.
  • [MeSH-major] Gene Expression Profiling. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358311.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA88361
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


41. Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M, Martinelli G: Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica; 2007 Mar;92(3):401-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
  • The emergence of resistance to the Bcr-Abl inhibitor imatinib mesylate in patients with Philadelphia chromosome-positive (Ph+) leukemia has prompted the development of second-generation compounds active against several imatinib-insensitive mutant forms of Bcr-Abl, including dasatinib (BMS-354825; Bristol-Myers Squibb).
  • [MeSH-major] Amino Acid Substitution. Antineoplastic Agents / pharmacology. Drug Resistance, Neoplasm / genetics. Fusion Proteins, bcr-abl / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Mutation, Missense. Neoplasm Proteins / genetics. Point Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Protein Kinase Inhibitors / pharmacology. Pyrimidines / pharmacology. Thiazoles / pharmacology

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339191.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Codon; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; RBZ1571X5H / Dasatinib
  •  go-up   go-down


42. Luczyński W, Krawczuk-Rybak M, Stasiak-Barmuta A: [Experimental and selected clinical aspects of active immunotherapy in leukemia]. Postepy Hig Med Dosw (Online); 2006;60:379-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experimental and selected clinical aspects of active immunotherapy in leukemia].
  • The aim of the review is to summarize current knowledge concerning active immunotherapy in leukemia.
  • Cells of acute lymphoblastic leukemia and chronic lymphocytic leukemia can be induced into antigen-presenting cells with the CD40 ligation system.
  • In many studies it was confimed that these cells stimulate auto- and/or allogeneic T-cell response.
  • Similar effects using different cytokines such as GM-CSF, TNF-alpha, and IL-4 can be observed in acute myeloid leukemia and myelodysplastic syndromes.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885908.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Cancer Vaccines
  • [Number-of-references] 51
  •  go-up   go-down


43. Chirivella S, Rajappa S, Sinha S, Eden T, Barr RD: Health-related quality of life among children with cancer in Hyderabad, India. Indian J Pediatr; 2009 Dec;76(12):1231-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of the children had acute lymphoblastic leukaemia.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. India. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Pediatr. 2010 Jul;77(7):825; author reply 826 [20589468.001]
  • [Cites] Pediatr Blood Cancer. 2005 Aug;45(2):230-6 [15920776.001]
  • [Cites] Pharmacoeconomics. 1995 Jun;7(6):503-20 [10155336.001]
  • [Cites] Med Pediatr Oncol. 1995 Sep;25(3):197-203 [7623729.001]
  • [Cites] Int J Cancer Suppl. 1999;12:2-9 [10679863.001]
  • [Cites] Int J Oncol. 2001 Aug;19(2):413-21 [11445861.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1333-9 [8826959.001]
  • [Cites] Pharmacoeconomics. 1995 Jun;7(6):490-502 [10155335.001]
  • [Cites] Pediatr Blood Cancer. 2004 Sep;43(3):215-23 [15266404.001]
  • [Cites] Health Qual Life Outcomes. 2003 Oct 16;1:54 [14613568.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(33):102-25 [15504922.001]
  • [Cites] Acta Paediatr. 2004 Oct;93(10):1356-62 [15499958.001]
  • [Cites] Lancet Oncol. 2002 Dec;3(12):710 [12473496.001]
  • (PMID = 19936653.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  •  go-up   go-down


44. Earle EA, Eiser C: Children's behaviour following diagnosis of acute lymphoblastic leukaemia: a qualitative longitudinal study. Clin Child Psychol Psychiatry; 2007 Apr;12(2):281-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children's behaviour following diagnosis of acute lymphoblastic leukaemia: a qualitative longitudinal study.
  • We interviewed 32 mothers of children newly diagnosed with Acute Lymphoblastic Leukaemia (ALL) shortly following diagnosis, 1 and 2 years later.
  • [MeSH-major] Child Behavior Disorders. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Quality of Life / psychology

  • MedlinePlus Health Information. consumer health - Child Behavior Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533941.001).
  • [ISSN] 1359-1045
  • [Journal-full-title] Clinical child psychology and psychiatry
  • [ISO-abbreviation] Clin Child Psychol Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. Bailey HD, Milne E, de Klerk N, Fritschi L, Bower C, Attia J, Armstrong BK: Representativeness of child controls recruited by random digit dialling. Paediatr Perinat Epidemiol; 2010 May;24(3):293-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study subjects were recruited from 2003 to 2006 for a national, population-based case-control study investigating causes of acute lymphoblastic leukaemia (ALL) in children <15 years of age in Australia.
  • [MeSH-major] Case-Control Studies. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Telephone

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20415759.001).
  • [ISSN] 1365-3016
  • [Journal-full-title] Paediatric and perinatal epidemiology
  • [ISO-abbreviation] Paediatr Perinat Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


46. Elliott MA, Litzow MR, Letendre LL, Wolf RC, Hanson CA, Tefferi A, Tallman MS: Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood; 2007 Dec 15;110(13):4172-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival.
  • In childhood acute lymphoblastic leukemia (ALL), a rapid decline of circulating leukemic blasts in response to induction chemotherapy or prednisone is one of the most important prognostic factors, not only for achieving remission but also for relapse-free survival (RFS).
  • However, in acute myeloid leukemia (AML) parameters of chemosensitivity have been restricted mainly to the rapidity of achievement of complete remission (CR) or the assessment of residual leukemic bone marrow blasts during aplasia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Blast Crisis / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2008 Feb 1;111(3):1746-7 [18223180.001]
  • (PMID = 17909077.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


47. Xicoy B, Ribera JM, Oriol A, Sanz MA, Abella E, Tormo M, del Potro E, Bueno J, Grande C, Fernández-Calvo J, Orts M, Novo A, Rivas C, Hernández-Rivas JM, Feliu E, Ortega JJ: [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients]. Med Clin (Barc); 2006 Jan 21;126(2):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients].
  • [Transliterated title] Significado pronóstico de los subtipos inmunológicos de la leucemia aguda linfoblástica T del adulto. Estudio de 81 pacientes.
  • BACKGROUND AND OBJECTIVE: T-cell acute lymphoblastic leukemia (ALL) includes 4 immunological subtypes: pro-T, pre-T, thymic or cortical and mature.
  • The objective of this study was to describe the clinical characteristics, the result of treatment and the prognosis of the immunological subtypes of T-cell ALL in 81 adult patients included in 2 protocols of the Spanish PETHEMA group (ALL-96 and ALL-93).
  • The main clinical and biological parameters as well as the rate of response to treatment, the frequency of complete remission , disease free survival and overall survival were compared in each T-cell ALL subtype.
  • Patients with mature T-cell ALL had a slow rate of response to treatment in comparison with patients wit pre-T and mature T-cell ALL but this did not translate to significant differences in frequency of complete remission (77% vs 94%), disease free survival (42% vs 46%) and overall survival (29% vs 47%).
  • CONCLUSIONS: Although patients with mature T-cell ALL had a slow rate of response to treatment and their survival tended to be shorter, in the present study there were no statistically significant differences in the prognosis of the different subtypes of T-cell ALL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426542.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


48. Tang Y, Xu X, Song H, Yang S, Shi S, Wei J: Long-term outcome of childhood acute lymphoblastic leukemia treated in China. Pediatr Blood Cancer; 2008 Sep;51(3):380-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of childhood acute lymphoblastic leukemia treated in China.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Treatment Failure. Treatment Refusal

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18506765.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Valik D, Sterba J, Bajciova V, Demlova R: Severe encephalopathy induced by the first but not the second course of high-dose methotrexate mirrored by plasma homocysteine elevations and preceded by extreme differences in pretreatment plasma folate. Oncology; 2005;69(3):269-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We observed extreme elevations of homocysteine in a 9-year-old boy presenting with leukemia treated with the ALL-BFM 95 protocol.
  • [MeSH-major] Brain / drug effects. Brain Diseases, Metabolic / chemically induced. Folic Acid / blood. Homocysteine / blood. Methotrexate / administration & dosage. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16166815.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Folic Acid Antagonists; 0LVT1QZ0BA / Homocysteine; 935E97BOY8 / Folic Acid; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


50. Hijiya N, Liu W, Sandlund JT, Jeha S, Razzouk BI, Ribeiro RC, Rubnitz JE, Howard SC, Kyzer EP, Redd DS, Cheng C, Rivera GK, Hudson MM, Relling MV, Pui CH: Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation. Leukemia; 2005 Aug;19(8):1399-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation.
  • To assess the prognosis of overt testicular disease at diagnosis of acute lymphoblastic leukemia, and any therapeutic role of irradiation for this involvement, we reviewed the data of 811 boys treated on St Jude studies Total X--XI (early period) and Total XII-XIV (recent period).
  • In the early period, patients with testicular leukemia had a poorer overall survival (OS) (P=0.003), event-free survival (EFS) (P=0.064), and higher cumulative incidence of relapse (P=0.041) than did other patients.
  • During the recent period, patients with and without overt testicular leukemia did not differ in OS (P=0.257), EFS (P=0.102), or cumulative incidence of relapse (P=0.51).
  • Both patients who received irradiation for residual testicular disease at the end of induction subsequently died of leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Testicular Neoplasms / radiotherapy


51. Kaplinsky C, Bielorai B, Keidan I: Intracranial pressure in pediatric patients with acute lymphoblastic leukemia. Pediatr Blood Cancer; 2009 Sep;53(3):513; author reply 514
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial pressure in pediatric patients with acute lymphoblastic leukemia.
  • [MeSH-major] Intracranial Pressure. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Blood Cancer. 2009 Mar;52(3):418-20 [19058211.001]
  • (PMID = 19418551.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


52. Tohda S, Sato T, Kogoshi H, Fu L, Sakano S, Nara N: Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors. Leuk Res; 2006 Nov;30(11):1385-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors.
  • A novel lymphoma cell line, designated TMD8 was established from cells of a patient with diffuse large B-cell lymphoma.
  • Cell growth was suppressed by gamma-secretase inhibitors (GSI).
  • It was reported that GSI suppressed growth of T-cell acute lymphoblastic leukemia (T-ALL) cell lines, which frequently had NOTCH1 mutations.
  • In addition to T-ALL, TMD8 is another unique cell line sensitive to GSI, and is useful to study effects of GSI in molecular targeting therapy.
  • [MeSH-major] Amyloid Precursor Protein Secretases / antagonists & inhibitors. Cell Line, Tumor. Cell Proliferation / drug effects. Dipeptides / pharmacology. Enzyme Inhibitors / pharmacology. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Oligopeptides / pharmacology
  • [MeSH-minor] Basic Helix-Loop-Helix Transcription Factors / drug effects. Basic Helix-Loop-Helix Transcription Factors / genetics. Cell Survival / drug effects. Fatal Outcome. Homeodomain Proteins / drug effects. Homeodomain Proteins / genetics. Humans. Intercellular Signaling Peptides and Proteins / genetics. Karyotyping. Ligands. Male. Membrane Proteins / genetics. Middle Aged. RNA, Messenger / drug effects. RNA, Messenger / genetics. Receptor, Notch1 / genetics. Receptor, Notch2 / genetics. Reverse Transcriptase Polymerase Chain Reaction. Structure-Activity Relationship

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2006 Nov;30(11):1331-2 [16934329.001]
  • (PMID = 16780947.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DLL4 protein, human; 0 / Dipeptides; 0 / Enzyme Inhibitors; 0 / Homeodomain Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / JAG2 protein, human; 0 / Ligands; 0 / Membrane Proteins; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / NOTCH1 protein, human; 0 / NOTCH2 protein, human; 0 / Oligopeptides; 0 / RNA, Messenger; 0 / Receptor, Notch1; 0 / Receptor, Notch2; 0 / benzyloxycarbonyl-isoleucyl-leucinal; 0 / benzyloxycarbonyl-leucyl-leucyl-norleucinal; 149348-15-2 / HES1 protein, human; EC 3.4.- / Amyloid Precursor Protein Secretases
  •  go-up   go-down


53. Fortune A, O'Leary H, Gilmore R, Chadwick N, Brennan L, Ní Chonghaile M, McCann SR, Browne PV, Conneally E, Vandenberghe E: T-lymphoblastic leukemia/lymphoma: a single center retrospective study of outcome. Leuk Lymphoma; 2010 Jun;51(6):1035-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-lymphoblastic leukemia/lymphoma: a single center retrospective study of outcome.
  • T-lymphoblastic leukemia/lymphoma (LBL and ALL) is a rare lymphoid malignancy typically presenting in adolescent and young adult males.
  • The successful use of intensified ALL protocols in patients <25 years with lymphoblastic malignancies without transplant prompted the Haematology Unit at St James's Hospital (SJH) to change practice in 2005 from transplanting in first complete remission (CR1) to treating patients <25 years with chemotherapy alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20443674.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Kuiper RP, Schoenmakers EF, van Reijmersdal SV, Hehir-Kwa JY, van Kessel AG, van Leeuwen FN, Hoogerbrugge PM: High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia; 2007 Jun;21(6):1258-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression.
  • Gross cytogenetic anomalies are traditionally being used as diagnostic, prognostic and therapeutic markers in the clinical management of cancer, including childhood acute lymphoblastic leukemia (ALL).
  • We detected multiple de novo genetic lesions, including gross aneuploidies and segmental gains and losses, some of which were subtle and affected single genes.
  • Many of these lesions involved recurrent (partially) overlapping deletions and duplications, containing various established leukemia-associated genes, such as ETV6, RUNX1 and MLL.
  • Importantly, the most frequently affected genes were those controlling G1/S cell cycle progression (e.g.
  • CDKN2A, CDKN1B and RB1), followed by genes associated with B-cell development.
  • The latter group includes microdeletions of the B-lineage transcription factors PAX5, EBF, E2-2 and IKZF1 (Ikaros), as well as genes with other established roles in B-cell development, that is RAG1 and RAG2, FYN, PBEF1 or CBP/PAG.
  • The fact that we frequently encountered multiple lesions affecting genes involved in cell cycle regulation and B-cell differentiation strongly suggests that both these processes need to be targeted independently and simultaneously to trigger ALL development.
  • [MeSH-major] Cell Cycle / genetics. Cell Differentiation / genetics. Genes, Neoplasm. Lymphocytes / cytology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


55. Zhu GH, Shi HW: [Granulocytic sarcoma secondary to acute lymphoblastic leukemia in a boy]. Zhonghua Er Ke Za Zhi; 2005 Mar;43(3):238
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granulocytic sarcoma secondary to acute lymphoblastic leukemia in a boy].
  • [MeSH-major] Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Sarcoma, Myeloid / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15833214.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


56. Miyatima Y, Ogawa A, Kuno K, Toda K, Suzuki K, Mituya A: [Mucoepidermoid carcinoma of the parotid gland as a secondary malignancy developed ten years after chemotherapy for childhood acute lymphoblastic leukemia]. Rinsho Ketsueki; 2007 Jun;48(6):491-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucoepidermoid carcinoma of the parotid gland as a secondary malignancy developed ten years after chemotherapy for childhood acute lymphoblastic leukemia].
  • We report on a case of mucoepidermoid carcinoma of the parotid gland following treatment of acute lymphoblastic leukemia (ALL) in childhood.
  • The female patient was diagnosed as having T-cell ALL at the age of 13 years.
  • [MeSH-major] Carcinoma, Mucoepidermoid / etiology. Neoplasms, Second Primary / etiology. Parotid Neoplasms / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy


57. Anderson BD, Schoenfeldt M: Clinical trials referral resource. Oncology (Williston Park); 2005 Jan;19(1):69-70, 73-4, 78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Child. Child Welfare. Germinoma / drug therapy. Humans. Lymphoma, Non-Hodgkin / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Retinoblastoma / drug therapy. Sarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743152.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Directory
  • [Publication-country] United States
  •  go-up   go-down


58. Aricò M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, Manabe A, Saha V, Baruchel A, Vettenranta K, Horibe K, Benoit Y, Pieters R, Escherich G, Silverman LB, Pui CH, Valsecchi MG: Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol; 2010 Nov 1;28(31):4755-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.
  • PURPOSE: In a previous analysis of 326 children with Philadelphia chromosome (Ph) -positive acute lymphoblastic leukemia (ALL) treated between 1986 and 1996, hematopoietic stem-cell transplantation from HLA-matched related donors, but not from unrelated donors, offered a superior outcome than chemotherapy alone.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2730-41 [9763557.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3110-8 [19059878.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5175-81 [19805687.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5168-74 [19805690.001]
  • [Cites] Leukemia. 2010 Feb;24(2):371-82 [20010620.001]
  • [Cites] Leukemia. 2010 Feb;24(2):406-18 [20010621.001]
  • [Cites] Leukemia. 2010 Feb;24(2):345-54 [20010622.001]
  • [Cites] Leukemia. 2010 Feb;24(2):265-84 [20010625.001]
  • [Cites] Leukemia. 2010 Feb;24(2):355-70 [20016527.001]
  • [Cites] Leukemia. 2010 Feb;24(2):309-19 [20016528.001]
  • [Cites] Leukemia. 2010 Feb;24(2):298-308 [20016530.001]
  • [Cites] Leukemia. 2010 Feb;24(2):285-97 [20016531.001]
  • [Cites] Leukemia. 2010 Feb;24(2):255-64 [20016536.001]
  • [Cites] Leukemia. 2010 Feb;24(2):320-34 [20016537.001]
  • [Cites] Leukemia. 2010 Feb;24(2):397-405 [20016538.001]
  • [Cites] Leukemia. 2010 Feb;24(2):335-44 [20016539.001]
  • [Cites] Leukemia. 2010 Feb;24(2):383-96 [20033052.001]
  • [Cites] Leukemia. 2010 Feb;24(2):253-4 [20145664.001]
  • [Cites] Blood. 2010 Apr 22;115(16):3206-14 [20154213.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Leukemia. 2004 Apr;18(4):693-702 [15044926.001]
  • [Cites] Klin Padiatr. 1987 May-Jun;199(3):151-60 [3306129.001]
  • [Cites] Blood. 1991 Jan 15;77(2):324-30 [1985699.001]
  • [Cites] Lancet. 1991 May 4;337(8749):1055-8 [1673492.001]
  • [Cites] Blood. 1991 Nov 1;78(9):2411-8 [1932753.001]
  • [Cites] Leukemia. 1996 Jun;10(6):957-63 [8667652.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1717-26 [9351539.001]
  • [Cites] Stat Med. 2007 Oct 30;26(24):4505-19 [17348080.001]
  • (PMID = 20876426.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA086011; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U24 CA114766
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / HLA Antigens; 0 / Protein Kinase Inhibitors
  • [Other-IDs] NLM/ PMC3020705
  •  go-up   go-down


59. An Q, Xue TY, Xu W, Gao JZ, Wu Y, Xu CP: [Effect of N-tosyl-L-phenylalnylchloromethyl ketone and dexamethasone on expression of nuclear transcription factor-kappaB in childhood acute lymphoblastic leukemia and its significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr;15(2):399-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of N-tosyl-L-phenylalnylchloromethyl ketone and dexamethasone on expression of nuclear transcription factor-kappaB in childhood acute lymphoblastic leukemia and its significance].
  • In order to investigate the effect of N-tosyl-L-phenylalnylchloromethyl ketone (TPCK) and dexamethasone (Dex) on expression of nuclear transcription factor-kappaB (NF-kappaB) in childhood acute lymphoblastic leukemia (ALL) and its significance, so as to provide the experimental basis for corresponding clinical treatment of ALL, in which NF-kappaB is taken as a target.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493356.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Protein Synthesis Inhibitors; 402-71-1 / Tosylphenylalanyl Chloromethyl Ketone; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


60. Sahu GR, Das BR: Alteration of p73 in pediatric de novo acute lymphoblastic leukemia. Biochem Biophys Res Commun; 2005 Feb 18;327(3):750-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of p73 in pediatric de novo acute lymphoblastic leukemia.
  • Aberrant DNA methylation of multiple promoter associated CpG islands is a frequent phenomenon in acute lymphoblastic leukemia (ALL).
  • [MeSH-major] DNA-Binding Proteins / genetics. Gene Expression Regulation, Neoplastic. Nuclear Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15649410.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


61. Sens MA, Zhou X, Weiland T, Cooley AM: Unexpected neoplasia in autopsies: potential implications for tissue and organ safety. Arch Pathol Lab Med; 2009 Dec;133(12):1923-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An autopsy of a registered tissue donor with strong preautopsy clinical assessment of a saddle pulmonary embolus revealed unsuspected acute lymphoblastic leukemia, prompting a review of the incidence of unsuspected neoplasia from a regional forensic autopsy practice.
  • [MeSH-major] Autopsy / statistics & numerical data. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Tissue Donors

  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961246.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Usvasalo A, Räty R, Harila-Saari A, Koistinen P, Savolainen ER, Vettenranta K, Knuutila S, Elonen E, Saarinen-Pihkala UM: Acute lymphoblastic leukemias with normal karyotypes are not without genomic aberrations. Cancer Genet Cytogenet; 2009 Jul;192(1):10-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemias with normal karyotypes are not without genomic aberrations.
  • Current cytogenetic techniques have enabled more accurate definition of genetic aberrations in the lymphoblasts of patients with acute lymphoblastic leukemia (ALL), at least in most cases.
  • [MeSH-major] Chromosome Aberrations. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480931.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalová K, Stark B, Harrison CJ, Teigler-Schlegel A, Johansson B: Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood; 2008 Feb 1;111(3):1575-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study.
  • Children with Down syndrome (DS) have a markedly increased risk of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
  • Unlike previous smaller series, a significant proportion of DS-ALLs had the typical B-cell precursor ALL abnormalities high hyperdiploidy (HeH; 11%) and t(12;21)(p13;q22) (10%).
  • [MeSH-major] Down Syndrome / complications. Down Syndrome / genetics. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


64. Lee DS, Kim YR, Cho HK, Lee CK, Lee JH, Cho HI: The presence of TEL/AML1 rearrangement and cryptic deletion of the TEL gene in adult acute lymphoblastic leukemia (ALL). Cancer Genet Cytogenet; 2005 Oct 15;162(2):176-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of TEL/AML1 rearrangement and cryptic deletion of the TEL gene in adult acute lymphoblastic leukemia (ALL).
  • TEL/AML1 (also known as ETV6/RUNX1) rearrangement is the most frequent genetic change in childhood B-acute lymphoblastic leukemia (ALL) and is associated with a favorable prognosis.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Deletion. Gene Rearrangement. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213368.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


65. Protas PT, Muszynska-Roslan K, Holownia A, Grabowska A, Krawczuk-Rybak M, Braszko JJ: Cerebrospinal fluid changes in the excitatory amino acids concentration caused by the standard treatment of acute lymphoblastic leukaemia in children do not correlate with their later cognitive functioning. Neuropediatrics; 2009 Dec;40(6):295-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrospinal fluid changes in the excitatory amino acids concentration caused by the standard treatment of acute lymphoblastic leukaemia in children do not correlate with their later cognitive functioning.
  • The aim of this study was to ascertain whether changes in the concentrations of cerebrospinal fluid excitatory amino acids (EAAs) contribute to neurotoxicity of the standard acute lymphoblastic leukaemia (ALL) treatment protocols.
  • [MeSH-major] Cognition / physiology. Excitatory Amino Acids / cerebrospinal fluid. Precursor Cell Lymphoblastic Leukemia-Lymphoma / cerebrospinal fluid. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20446226.001).
  • [ISSN] 1439-1899
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Excitatory Amino Acids
  •  go-up   go-down


66. Nakajima D, Fukushima K, Yamanouchi H: [Neurological complications during and after the treatment of acute lymphocytic leukemia]. No To Hattatsu; 2006 May;38(3):195-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neurological complications during and after the treatment of acute lymphocytic leukemia].
  • To explore the frequency and prognosis of neurological complications of acute lymphocytic leukemia, retrospective studies were made of patients with acute lymphocytic leukemia.
  • We conclude that careful management is required in the treatment of acute lymphocytic leukemia, because of the persistence of neurological complications, although their severity is decreasing with advances in treatment.
  • [MeSH-major] Cerebrovascular Disorders / etiology. Dementia, Vascular / etiology. Epilepsy / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Wernicke Encephalopathy / etiology

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16715933.001).
  • [ISSN] 0029-0831
  • [Journal-full-title] No to hattatsu. Brain and development
  • [ISO-abbreviation] No To Hattatsu
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


67. Ledet DS, Wheless JW, Rubnitz JE, Brannon Morris E: Levetiracetam as monotherapy for seizures in a neonate with acute lymphoblastic leukemia. Eur J Paediatr Neurol; 2010 Jan;14(1):78-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levetiracetam as monotherapy for seizures in a neonate with acute lymphoblastic leukemia.
  • Congenital acute lymphoblastic leukemia (ALL) is a relatively rare disorder that is characterized by frequent central nervous system involvement that may increase the risk for seizures.
  • Peripheral blood smear contained blastocytes and DNA analysis confirmed B-cell ALL.
  • We report the successful use of levetiracetam monotherapy after Phenobarbital load in a neonate with leukemia and localization-related epilepsy.
  • [MeSH-major] Anticonvulsants / therapeutic use. Piracetam / analogs & derivatives. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Seizures / drug therapy. Seizures / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Seizures.
  • Hazardous Substances Data Bank. PIRACETAM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
  • [Cites] Blood. 2000 Jul 1;96(1):24-33 [10891426.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1981 Fall;3(3):287-96 [7025684.001]
  • [Cites] J Child Neurol. 2008 May;23(5):582-4 [18448575.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Oct;323(1):165-73 [17636003.001]
  • [Cites] Br J Clin Pharmacol. 2006 Mar;61(3):246-55 [16487217.001]
  • (PMID = 19186085.001).
  • [ISSN] 1532-2130
  • [Journal-full-title] European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  • [ISO-abbreviation] Eur. J. Paediatr. Neurol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; 230447L0GL / etiracetam; ZH516LNZ10 / Piracetam
  • [Other-IDs] NLM/ NIHMS520881; NLM/ PMC3902105
  •  go-up   go-down


68. Alikasifoglu A, Yetgin S, Cetin M, Tuncer M, Gumruk F, Gurgey A, Yordam N: Bone mineral density and serum bone turnover markers in survivors of childhood acute lymphoblastic leukemia: comparison of megadose methylprednisolone and conventional-dose prednisolone treatments. Am J Hematol; 2005 Oct;80(2):113-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone mineral density and serum bone turnover markers in survivors of childhood acute lymphoblastic leukemia: comparison of megadose methylprednisolone and conventional-dose prednisolone treatments.
  • During recent decades, the survival rate after childhood acute lymphoblastic leukemia (ALL) has improved substantially; consequently, the long-term side effects of ALL and its treatment have gained attention, of which osteoporosis is one of the most important.
  • [MeSH-major] Bone Density / drug effects. Bone Remodeling / drug effects. Methylprednisolone / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisolone / adverse effects


69. Rojas de Morales T, Navas R, Viera N, Alvarez CJ, Chaparro N, Griman D: pH and salivary sodium bicarbonate during the administration protocol for methotrexate in children with leukemia. Med Oral Patol Oral Cir Bucal; 2007 Oct;12(6):E435-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] pH and salivary sodium bicarbonate during the administration protocol for methotrexate in children with leukemia.
  • OBJECTIVE: To analyze the behavior of pH and sodium bicarbonate (NAHCO3) in the saliva of patients with leukemia during the administration protocol for Methotrexate (Mtx).
  • MATERIALS AND METHODS: A controlled clinical essay was carried out on 23 patients between 4 and 18 years of age with high-risk Acute Lymphoblastic Leukemia.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Methotrexate / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Saliva / chemistry. Saliva / metabolism. Sodium Bicarbonate / analysis

  • Hazardous Substances Data Bank. SODIUM BICARBONATE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909509.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 8MDF5V39QO / Sodium Bicarbonate; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


70. Ong V, Liem NL, Schmid MA, Verrills NM, Papa RA, Marshall GM, Mackenzie KL, Kavallaris M, Lock RB: A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts. J Pharmacol Exp Ther; 2008 Feb;324(2):434-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.
  • The microtubule-depolymerizing drug, vincristine, is effective in the treatment of acute lymphoblastic leukemia (ALL).
  • Although vincristine resistance mechanisms have been extensively characterized in cell lines, their clinical relevance is poorly understood.
  • In vitro vincristine sensitivity determined by a stromal coculture, murine bone marrow stromal cell line (MS-5), assay, but not methyl-thiazolyl-tetrazolium metabolic activity assay, significantly correlated (P = 0.05) with the length of the patients' first remission.
  • [MeSH-major] Drug Resistance, Neoplasm / physiology. Microtubules / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Vincristine / therapeutic use. Xenograft Model Antitumor Assays / methods
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Mice. Polymers / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986648.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM-42216
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Polymers; 5J49Q6B70F / Vincristine
  •  go-up   go-down


71. Kennedy-Nasser AA, Bollard CM, Myers GD, Leung KS, Gottschalk S, Zhang Y, Liu H, Heslop HE, Brenner MK, Krance RA: Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant; 2008 Nov;14(11):1245-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen.
  • HLA-matched sibling donor (MSD) stem cell transplantation can cure>60% of pediatric patients with acute lymphoblastic leukemia (ALL), but <30% of patients will have a sibling donor.
  • The addition of alemtuzumab (Campath 1-H) to AD transplants produces in vivo T cell depletion, which may reduce the risk for GVHD.
  • We now report the outcome for 83 children with ALL (41 MSD, 42 AD) undergoing stem cell transplantation in first or second complete remission.
  • For children undergoing stem cell transplantation (SCT) from alternative donors, alemtuzumab with a myeloablative conditioning regimen resulted in DFS comparable to MSD.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Neoplasm / administration & dosage. Antineoplastic Agents / administration & dosage. Donor Selection. Hematopoietic Stem Cell Transplantation. Living Donors. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Siblings. Transplantation Conditioning

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18940679.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


72. Karbasian-Esfahani M, Wiernik PH, Yeddu M, Abebe L: Leukemic infiltration of the breast in acute lymphocytic leukemia (ALL). Hematology; 2008 Apr;13(2):101-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemic infiltration of the breast in acute lymphocytic leukemia (ALL).
  • Extramedullary leukemic infiltration of the breast in adult acute lymphocytic leukemia (ALL) is rare.
  • [MeSH-major] Breast Neoplasms / secondary. Leukemic Infiltration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616877.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 35
  •  go-up   go-down


73. Ye QD, Gu LJ, Tang JY, Xue HL, Chen J, Pan C, Chen J, Dong L, Zhou M, Jiang LM: [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun;10(3):333-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
  • OBJECTIVE: To study the role of minimal residual disease (MRD) in the evaluation of therapeutic effectiveness of childhood B-cell acute lymphoblastic leukemia (ALL).
  • METHODS: MRD testing was performed in 124 children with B-cell ALL, who were newly diagnosed and enrolled in the ALL-XH-99 treatment protocol from September 2001 to April 2005MRD was determined by 4-color flow cytometry in the different time points during the treatment period.
  • Multivariate analysis confirmed that the MRD level after induction chemotherapy together with the reaction to prednisone, the bone marrow features on the 19th day of induction, and the fusion gene with BCR-ABL or MLL-AF4 had prognostic significance in childhood B-cell ALL.
  • CONCLUSIONS: The MRD level in the whole course of therapy is an important outcome indicator in childhood B cell ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


74. Landmeier S, Altvater B, Pscherer S, Meltzer J, Sebire N, Pule M, Vera J, Hotfilder M, Juergens H, Vormoor J, Rossig C: Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo. Leukemia; 2010 May;24(5):1080-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo.
  • [MeSH-major] Antigens, CD19 / immunology. Graft vs Leukemia Effect / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Receptors, Immunologic / immunology. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Cytotoxic / transplantation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20220773.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Receptors, Immunologic
  •  go-up   go-down


75. Litzow MR: Therapy of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults: new paradigms. Future Oncol; 2009 Sep;5(7):1039-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults: new paradigms.
  • Although the outcomes for adults with acute lymphoblastic leukemia (ALL) lag behind the stunningly successful results seen in children, new paradigms and new discoveries bring hope that this disparity will steadily lessen.
  • Recent donor-versus-no-donor comparisons in the allogeneic transplant setting highlight a potent graft-versus-leukemia effect in ALL, and the application of reduced intensity conditioning transplants may exploit this effect while reducing nonrelapse mortality.
  • New therapeutic targets, such as CD22 in precusor B-cell ALL and mutations in NOTCH1 in T-cell ALL, are being exploited in clinical trials.
  • [MeSH-major] Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19792972.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 63
  •  go-up   go-down


76. Han SS, Yun H, Son DJ, Tompkins VS, Peng L, Chung ST, Kim JS, Park ES, Janz S: NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Mol Cancer; 2010 Apr 30;9:97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.
  • BACKGROUND: Myc is a well known driver of lymphomagenesis, and Myc-activating chromosomal translocation is the recognized hallmark of Burkitt lymphoma, an aggressive form of non-Hodgkin's lymphoma.
  • These mice, designated iMyc E mu, readily develop B-cell lymphoma.
  • To study the mechanism of Myc-induced lymphoma, we analyzed signaling pathways in lymphoblastic B-cell lymphomas (LBLs) from iMyc E mu mice, and an LBL-derived cell line, iMyc E mu-1.
  • Blocking AKT activation by inhibiting PI3K reduced iMyc E mu-1 cell proliferation and caused apoptosis, via downregulation of NF-kappaB and STAT3 activity and a reduction of Myc levels.
  • Co-treatment with NF-kappaB, STAT3 or/and PI3K inhibitors led to additive inhibition of iMyc E mu-1 cell proliferation, suggesting that these signaling pathways converge.
  • CONCLUSIONS: Our findings support the notion that constitutive activation of NF-kappaB and STAT3 depends on upstream signaling through PI3K, and that this activation is important for cell survival and proliferation, as well as for maintaining the level of Myc.
  • Together, these data implicate crosstalk among NF-kappaB, STAT3 and PI3K in the development of iMyc E mu B-cell lymphomas.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 1997 Jul;7(1):1-11 [9252115.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] Cell. 1998 Oct 2;95(1):29-39 [9778245.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1616-32 [16285960.001]
  • [Cites] Mol Cancer. 2005;4:40 [16277667.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1877-83 [16287065.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4540-8 [16497967.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1668-76 [16645163.001]
  • [Cites] Neoplasia. 2006 Sep;8(9):733-46 [16984731.001]
  • [Cites] Biochem Pharmacol. 2006 Oct 30;72(9):1069-80 [16854381.001]
  • [Cites] Histopathology. 2008 Oct;53(4):441-9 [18983609.001]
  • [Cites] Hum Pathol. 2009 Jan;40(1):75-82 [18755494.001]
  • [Cites] Cancer Cell. 2008 Dec 9;14(6):447-57 [19061836.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1250-8 [19228728.001]
  • [Cites] Cancer Cell. 2009 Apr 7;15(4):283-93 [19345327.001]
  • [Cites] Adv Cancer Res. 2005;94:29-86 [16095999.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3410-5 [9787181.001]
  • [Cites] J Exp Med. 1999 Jan 4;189(1):63-73 [9874564.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):419-24 [10208463.001]
  • [Cites] Nature. 1999 Sep 2;401(6748):86-90 [10485711.001]
  • [Cites] Clin Immunol. 1999 Nov;93(2):152-61 [10527691.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):439-44 [15542427.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1221-4 [15467468.001]
  • [Cites] Science. 2005 Jan 14;307(5707):269-73 [15653507.001]
  • [Cites] J Pathol. 2005 Mar;205(4):498-506 [15714459.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1306-15 [15735016.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):26-34 [15790433.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6817-30 [17072330.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2293-302 [17164350.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1396-408 [17510282.001]
  • [Cites] Biol Pharm Bull. 2007 Oct;30(10):1860-4 [17917251.001]
  • [Cites] PLoS Pathog. 2007 Nov;3(11):e166 [17997602.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1515-23 [17951530.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3701-13 [18160665.001]
  • [Cites] Diagn Mol Pathol. 2008 Sep;17(3):159-65 [18382359.001]
  • [Cites] Int Immunol. 1999 Jun;11(6):871-9 [10360960.001]
  • [Cites] Nature. 1999 Sep 2;401(6748):82-5 [10485710.001]
  • [Cites] Cancer Cell. 2005 May;7(5):425-31 [15894263.001]
  • [Cites] Nat Rev Immunol. 2005 Jun;5(6):435-45 [15905862.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2005;8(2):108-18 [15724144.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):561-73 [15950905.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(15):6592-602 [16024795.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4688-93 [15928251.001]
  • [Cites] Nat Rev Immunol. 2005 Oct;5(10):749-59 [16175180.001]
  • [Cites] Genes Cells. 2005 Nov;10(11):1051-63 [16236134.001]
  • [Cites] Leuk Lymphoma. 2005 Dec;46(12):1765-73 [16263580.001]
  • [Cites] Cell. 2000 Feb 18;100(4):387-90 [10693755.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1541-5 [10749120.001]
  • [Cites] Annu Rev Immunol. 2000;18:621-63 [10837071.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2548-56 [10851053.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2628-37 [10851062.001]
  • [Cites] FEBS Lett. 2001 Apr 20;495(1-2):71-6 [11322950.001]
  • [Cites] Blood. 2001 Aug 1;98(3):762-70 [11468177.001]
  • [Cites] Science. 2001 Aug 31;293(5535):1653-7 [11533489.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):279-86 [11703322.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1143-8 [11994402.001]
  • [Cites] Oncogene. 2002 May 30;21(24):3898-908 [12032828.001]
  • [Cites] Science. 2002 May 31;296(5573):1655-7 [12040186.001]
  • [Cites] Biochem J. 2002 Oct 1;367(Pt 1):97-105 [12057007.001]
  • [Cites] Nat Rev Immunol. 2002 Oct;2(10):725-34 [12360211.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):920-32 [12461565.001]
  • [Cites] Mol Cell. 2002 Dec;10(6):1283-94 [12504005.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Nov;82(4-5):369-76 [12589944.001]
  • [Cites] Leukemia. 2003 Mar;17(3):590-603 [12646949.001]
  • [Cites] Immunology. 2003 Apr;108(4):539-47 [12667216.001]
  • [Cites] Cell Signal. 2003 Jun;15(6):625-36 [12681450.001]
  • [Cites] J Immunol. 2003 Jul 1;171(1):88-95 [12816986.001]
  • [Cites] J Cell Physiol. 2003 Nov;197(2):157-68 [14502555.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6666-73 [14583460.001]
  • [Cites] J Biol Chem. 2004 Jan 16;279(3):1768-76 [14593105.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):726-34 [14737107.001]
  • [Cites] J Am Soc Nephrol. 2004 Mar;15(3):585-91 [14978160.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):533-8 [3906410.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(12):4727-31 [2191300.001]
  • [Cites] Cell. 1994 Apr 8;77(1):63-71 [7512451.001]
  • [Cites] J Exp Med. 1995 Mar 1;181(3):1169-77 [7869034.001]
  • [Cites] Cell. 1995 Jul 28;82(2):241-50 [7543024.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):5015-25 [8756660.001]
  • [Cites] Cell. 1996 Oct 4;87(1):13-20 [8858144.001]
  • [Cites] EMBO J. 1996 Sep 2;15(17):4682-90 [8887559.001]
  • (PMID = 20433747.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50CA097274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / STAT3 Transcription Factor; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  • [Other-IDs] NLM/ PMC2876994
  •  go-up   go-down


77. Laane E, Björklund E, Mazur J, Lönnerholm G, Söderhäll S, Porwit A: Dendritic cell regeneration in the bone marrow of children treated for acute lymphoblastic leukaemia. Scand J Immunol; 2007 Nov;66(5):572-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell regeneration in the bone marrow of children treated for acute lymphoblastic leukaemia.
  • We investigated DC levels by flow cytometry in BM at diagnosis, during and post-treatment in 76 children with acute lymphoblastic leukaemia (ALL).
  • However, the levels of pDC and mDC were significantly higher in T-precursor ALL patients when compared with B-precursor ALL patient group (P = 0.044 and 0.041 respectively).
  • In B-precursor SR ALL patients, mDC levels but not pDC levels decreased during prolonged maintenance treatment, remaining reduced at the end of treatment (P = 0.032) and at 6 months post-treatment (P = 0.028).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Cells / drug effects. Dendritic Cells / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892461.001).
  • [ISSN] 0300-9475
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


78. Kancha RK, von Bubnoff N, Miething C, Peschel C, Götze KS, Duyster J: Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation. Haematologica; 2008 Nov;93(11):1718-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment with imatinib is very effective in Bcr-Abl positive leukemia.
  • Using leptomycin B, a nuclear export blocker, it has been shown that reactivated nuclear Bcr-Abl kinase activity can induce cell death, thus presenting an interesting potential treatment option for imatinib resistant disease.
  • Here we show that the combination of imatinib and leptomycin B effectively induces cell death in imatinib-resistant Ba/F3 cells which display Bcr-Abl amplification or signs of clonal evolution.
  • [MeSH-minor] Benzamides. Cell Line, Tumor. Cell Survival / drug effects. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 9. Colony-Forming Units Assay. Fatty Acids, Unsaturated / pharmacology. Fusion Proteins, bcr-abl. Humans. Imatinib Mesylate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Mutation. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728023.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Fatty Acids, Unsaturated; 0 / Piperazines; 0 / Pyrimidines; 87081-35-4 / leptomycin B; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


79. Schmiegelow K, Vestergaard T, Nielsen SM, Hjalgrim H: Etiology of common childhood acute lymphoblastic leukemia: the adrenal hypothesis. Leukemia; 2008 Dec;22(12):2137-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiology of common childhood acute lymphoblastic leukemia: the adrenal hypothesis.
  • The pattern of infections in the first years of life modulates our immune system, and a low incidence of infections has been linked to an increased risk of common childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Hypothalamo-Hypophyseal System / immunology. Infection / immunology. Pituitary-Adrenal System / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology


80. Tsurusawa M, Yumura-Yagi K, Ohara A, Hara J, Katano N, Tsuchida M, Japanese Study Groups: Survival outcome after the first central nervous system relapse in children with acute lymphoblastic leukemia: a retrospective analysis of 79 patients in a joint program involving the experience of three Japanese study groups. Int J Hematol; 2007 Jan;85(1):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival outcome after the first central nervous system relapse in children with acute lymphoblastic leukemia: a retrospective analysis of 79 patients in a joint program involving the experience of three Japanese study groups.
  • In a retrospective review of the survival outcome of children with isolated central nervous system (CNS) relapse of acute lymphoblastic leukemia (ALL), we identified 79 patients with CNS relapse among the eligible patients enrolled in ALL trials of 3 Japanese pediatric oncology study groups (Japanese Children's Cancer and Leukemia Study Group [JCCLSG], Tokyo Children's Cancer Study Group [TCCSG], and Japan Association of Childhood Leukemia Study [JACLS]) between 1989 and 1999.
  • [MeSH-major] Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / secondary. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1993 Feb;11(2):271-8 [8426204.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3745-52 [10577846.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1646-54 [3309198.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1166-72 [1878583.001]
  • [Cites] J Clin Oncol. 1985 Jun;3(6):776-81 [3891922.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] Pediatr Hematol Oncol. 2004 Apr-May;21(3):279-89 [15202168.001]
  • [Cites] Rinsho Ketsueki. 1989 Jul;30(7):999-1004 [2810802.001]
  • [Cites] Med Pediatr Oncol. 1999 Apr;32(4):259-6 [10102019.001]
  • [Cites] Int J Hematol. 2002 Jul;76(1):61-8 [12138898.001]
  • [Cites] Acta Paediatr Jpn. 1991 Aug;33(4):540-7 [1792914.001]
  • [Cites] Cancer. 1989 May 15;63(10):2066-72 [2702576.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] Med Pediatr Oncol. 1995 Nov;25(5):372-8 [7674994.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):333-8 [7844594.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2295-306 [11187921.001]
  • (PMID = 17261500.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


81. Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J: Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood; 2010 Oct 21;116(16):2908-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe.
  • We therefore decided to evaluate the presence of leukemic cells in cryopreserved ovarian tissue from 18 leukemic patients: 6 with chronic myeloid leukemia (CML) and 12 with acute lymphoblastic leukemia (ALL).
  • In conclusion, this study demonstrates, by quantitative RT-PCR, ovarian contamination by malignant cells in acute as well as chronic leukemia, whereas histology fails to do so.
  • [MeSH-major] Cryopreservation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Ovary / pathology. Ovary / transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


82. Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijs-Gladdines JG, Kooi C, Smits WK, Sonneveld E, Veerman AJ, Kamps WA, Horstmann M, Petricoin EF 3rd, Pieters R, Meijerink JP: NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia; 2010 Dec;24(12):2014-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.
  • Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW7 is a frequent phenomenon in T-cell acute lymphoblastic leukemia (T-ALL).
  • We retrospectively investigated the relevance of NOTCH1/FBXW7 mutations for pediatric T-ALL patients enrolled on Dutch Childhood Oncology Group (DCOG) ALL7/8 or ALL9 or the German Co-Operative Study Group for Childhood Acute Lymphoblastic Leukemia study (COALL-97) protocols.
  • NOTCH1-activating mutations were less frequently associated with mature T-cell developmental stage.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prednisone / therapeutic use. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2010 Dec;24(12):2003-4 [21157484.001]
  • (PMID = 20861909.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Homeodomain Proteins; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; 0 / TLX3 protein, human; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases; VB0R961HZT / Prednisone
  •  go-up   go-down


83. Akahane D, Gotoh A, Takaku T, Iwase O, Ohyashiki K: Pseudothrombocytes detected by two-color flowcytometry in acute lymphoblastic leukemia (ALL-L3). Leuk Res; 2006 Sep;30(9):1211-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudothrombocytes detected by two-color flowcytometry in acute lymphoblastic leukemia (ALL-L3).
  • [MeSH-major] Blood Platelets / pathology. Flow Cytometry. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Aged. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. False Positive Reactions. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16494943.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


84. Bakhshi S, Arya LS: Conjunctival mass: rare site of extramedually relapse in childhood acute lymphoblastic leukemia. J Assoc Physicians India; 2005 Feb;53:160-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival mass: rare site of extramedually relapse in childhood acute lymphoblastic leukemia.
  • [MeSH-major] Conjunctiva / pathology. Conjunctival Neoplasms / secondary. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Assoc Physicians India. 2005 Mar;53:199. Bakhsi, S [corrected to Bakhshi, S]
  • (PMID = 15847046.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


85. Goldsby RE, Liu Q, Nathan PC, Bowers DC, Yeaton-Massey A, Raber SH, Hill D, Armstrong GT, Yasui Y, Zeltzer L, Robison LL, Packer RJ: Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol; 2010 Jan 10;28(2):324-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.
  • PURPOSE: Children with acute lymphoblastic leukemia (ALL) are often cured, but the therapies they receive may be neurotoxic.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2000 Jun;25(11):1191-6 [10849532.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2319-27 [19364957.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] Cancer. 2003 May 15;97(10):2588-96 [12733158.001]
  • [Cites] Eur J Cancer. 2004 Jun;40(9):1346-50 [15177494.001]
  • [Cites] J Clin Epidemiol. 2004 Sep;57(9):933-44 [15504636.001]
  • [Cites] Lancet. 1981 Nov 7;2(8254):1015-8 [6118478.001]
  • [Cites] Arch Dis Child. 1983 Dec;58(12):953-8 [6197936.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1984 Summer;6(2):115-21 [6589968.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1984 Summer;6(2):183-90 [6465470.001]
  • [Cites] J Clin Neuropsychol. 1984 Aug;6(3):325-36 [6590573.001]
  • [Cites] Lancet. 1984 Dec 22;2(8417-8418):1422-4 [6151043.001]
  • [Cites] Semin Oncol. 1985 Jun;12(2):131-48 [3892694.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):963-8 [3459573.001]
  • [Cites] Ophthalmology. 1988 Feb;95(2):151-5 [3173990.001]
  • [Cites] J Child Psychol Psychiatry. 1988 Nov;29(6):839-52 [3069852.001]
  • [Cites] J Child Neurol. 1989 Jul;4(3):208-13 [2768785.001]
  • [Cites] Arch Dis Child. 1990 Apr;65(4):416-22 [2346334.001]
  • [Cites] Stat Med. 1990 May;9(5):505-14 [2190287.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1348-56 [2072138.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1913-7 [1913542.001]
  • [Cites] J Clin Oncol. 1992 May;10(5):810-7 [1569453.001]
  • [Cites] Eur J Pediatr. 1993 Feb;152(2):115-9 [8444217.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):839-49 [8487048.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1289-95 [8413409.001]
  • [Cites] Epilepsia. 1995 Aug;36(8):831-6 [7635103.001]
  • [Cites] Med Pediatr Oncol. 1996 Dec;27(6):551-5 [8888816.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17(2):295-310 [8938302.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):51-6 [9420072.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1712-22 [9586883.001]
  • [Cites] Med Pediatr Oncol. 1998 Aug;31(2):86-90 [9680932.001]
  • [Cites] Cancer. 2005 Dec 1;104(11 Suppl):2557-64 [16247780.001]
  • [Cites] Leuk Res. 2006 May;30(5):537-41 [16249027.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5277-82 [17088567.001]
  • [Cites] Arch Pediatr Adolesc Med. 2007 Aug;161(8):798-806 [17679663.001]
  • [Cites] Qual Life Res. 2007 Sep;16(7):1211-20 [17624814.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] J Neurooncol. 2008 May;87(3):279-86 [18209952.001]
  • [Cites] Med Pediatr Oncol. 2000 Nov;35(5):449-55 [11070476.001]
  • (PMID = 19917844.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA055727; United States / NCI NIH HHS / CA / U24 CA55727
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2815720
  •  go-up   go-down


86. Lightfoot TJ, Johnston WT, Painter D, Simpson J, Roman E, Skibola CF, Smith MT, Allan JM, Taylor GM, United Kingdom Childhood Cancer Study: Genetic variation in the folate metabolic pathway and risk of childhood leukemia. Blood; 2010 May 13;115(19):3923-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variation in the folate metabolic pathway and risk of childhood leukemia.
  • Studies of childhood leukemia and the potential etiologic role of genetic variation in folate metabolism have produced conflicting findings and have often been based on small numbers.
  • We investigated the association between polymorphisms in key folate metabolism enzymes (MTHFR 677 C>T, MTHFR 1298 A>C, SHMT1 1420 C>T, MTR 2756 A>G, TS 1494del6, and TS 28bp repeat) in 939 cases of childhood acute lymphoblastic leukemia (ALL) and 89 cases of acute myeloid leukemia (AML) recruited into the United Kingdom Childhood Cancer Study.
  • These data suggest that genetic variation in methionine synthase could mediate risk of childhood leukemia, either via effects on DNA methylation or via effects on fetal growth and development.
  • [MeSH-major] Folic Acid / metabolism. Genetic Variation / genetics. Glycine Hydroxymethyltransferase / genetics. Leukemia, Myeloid, Acute / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Phosphotransferases (Alcohol Group Acceptor) / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 May 15;99(10):3786-91 [11986237.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8242-7 [12048236.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3361-4 [12067974.001]
  • [Cites] Br J Cancer. 2002 Oct 21;87(9):994-9 [12434291.001]
  • [Cites] Am J Hematol. 2003 Jul;73(3):154-60 [12827651.001]
  • [Cites] Biotechnol Lett. 2003 Jul;25(13):1031-6 [12889810.001]
  • [Cites] Blood. 2004 Jan 1;103(1):252-7 [12958073.001]
  • [Cites] Am J Epidemiol. 2004 Mar 1;159(5):423-43 [14977639.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Jul 15;198(2):75-85 [15236946.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):104-17 [15313583.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2155-62 [15198953.001]
  • [Cites] Nucleic Acids Res. 1987 Feb 11;15(3):1259-70 [3029702.001]
  • [Cites] Hum Mol Genet. 1996 Dec;5(12):1867-74 [8968737.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3290-5 [9096386.001]
  • [Cites] Thromb Haemost. 1997 Jul;78(1):523-6 [9198208.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1044-51 [9545395.001]
  • [Cites] Annu Rev Genet. 1998;32:495-519 [9928489.001]
  • [Cites] Mol Genet Metab. 1999 Aug;67(4):317-23 [10444342.001]
  • [Cites] Genet Epidemiol. 1999 Nov;17(4):298-309 [10520212.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4632-42 [15542813.001]
  • [Cites] Blood. 2005 Jan 15;105(2):906-7 [15632215.001]
  • [Cites] Electrophoresis. 2005 Feb;26(3):710-5 [15690424.001]
  • [Cites] BMC Med Genet. 2005 May 27;6:23 [15921520.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Aug;27(8):425-9 [16096524.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2999-3003 [16365025.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):229-32 [16450391.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):147-51 [16123993.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1956-63 [17035405.001]
  • [Cites] Eur J Epidemiol. 2006;21(7):501-10 [16897583.001]
  • [Cites] Leukemia. 2007 Feb;21(2):320-5 [17136115.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12810-5 [10536004.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1073-102 [10737392.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1381-5 [11142426.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4004-9 [11274424.001]
  • [Cites] Mol Genet Metab. 2001 Jun;73(2):164-72 [11386852.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):616-8 [11736945.001]
  • [Cites] Lancet. 2001 Dec 8;358(9297):1935-40 [11747917.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):786-92 [17454638.001]
  • [Cites] BMC Public Health. 2007;7:136 [17605825.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jan;57(1):53-61 [17622527.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2421-30 [18703816.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):276.e1-8 [18771981.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2284-9 [19020309.001]
  • [Cites] Hum Mol Genet. 2009 Nov 1;18(21):4054-65 [19679565.001]
  • [Cites] Cancer Epidemiol. 2009 Oct;33(3-4):257-60 [19736055.001]
  • (PMID = 20101025.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NCI NIH HHS / CA / CA104862; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.2.1 / Glycine Hydroxymethyltransferase; EC 2.1.2.1 / SHMT protein, human; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.100 / 5-methylthioribose kinase
  • [Other-IDs] NLM/ PMC2869556
  •  go-up   go-down


87. Buizer AI, de Sonneville LM, van den Heuvel-Eibrink MM, Veerman AJ: Behavioral and educational limitations after chemotherapy for childhood acute lymphoblastic leukemia or Wilms tumor. Cancer; 2006 May 1;106(9):2067-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Behavioral and educational limitations after chemotherapy for childhood acute lymphoblastic leukemia or Wilms tumor.
  • The purpose of this study was to evaluate behavioral and educational functioning in survivors of childhood acute lymphoblastic leukemia (ALL) or a Wilms tumor.
  • [MeSH-major] Child Behavior Disorders / etiology. Learning Disorders / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology


88. Butler RW, Haser JK: Neurocognitive effects of treatment for childhood cancer. Ment Retard Dev Disabil Res Rev; 2006;12(3):184-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is an important distinction for both leukemia and brain tumors.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Brain Neoplasms / therapy. Cognition Disorders / etiology. Cranial Irradiation / adverse effects. Developmental Disabilities / etiology. Intellectual Disability / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Developmental Disabilities.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17061287.001).
  • [ISSN] 1080-4013
  • [Journal-full-title] Mental retardation and developmental disabilities research reviews
  • [ISO-abbreviation] Ment Retard Dev Disabil Res Rev
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA83936
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 75
  •  go-up   go-down


89. Liu J, Zhang LQ, Hu Q, Lin HH, Liu AG, Tao HF, Song YQ, Zhang XL: [Expression of Daxx in children with acute leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb;9(1):33-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of Daxx in children with acute leukemia].
  • OBJECTIVE: To investigate Daxx expression and its clinical significance in children with acute leukemia.
  • METHODS: The expression of Daxx protein was detected by immunohistochemical assay in 50 children with newly diagnosed acute leukemia (34 cases of acute lymphocytic leukemia and 16 cases of acute non-lymphocytic leukemia).
  • RESULTS: Daxx protein was expressed in 38.0% of 50 children with acute leukemia, which was significantly higher than that of the control group (5.0%) (P < 0.05).
  • The children with acute non-lymphocytic leukemia had significantly higher Daxx expression levels (62.5%) than those with acute lymphocytic leukemia (26.5%; P < 0.05) as well as the control group (P < 0.05).
  • There were no significant differences in the Daxx expression between acute lymphocytic leukemia children and the control group.
  • Daxx protein was expressed in 55.6% of high risk group of acute lymphocytic leukemia but it was not expressed in standard risk group of acute lymphocytic leukemia (P < 0.05).
  • CONCLUSIONS: Daxx expression is abnormal in children with acute leukemia and associated with some clinical features of acute leukemia, suggesting that it may play an important role in the genesis and development of acute leukemia.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Leukemia, Myeloid, Acute / metabolism. Nuclear Proteins / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306074.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DAXX protein, human; 0 / NF-kappa B; 0 / Nuclear Proteins
  •  go-up   go-down


90. Taylor KH, Pena-Hernandez KE, Davis JW, Arthur GL, Duff DJ, Shi H, Rahmatpanah FB, Sjahputera O, Caldwell CW: Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res; 2007 Mar 15;67(6):2617-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia.
  • This study examined DNA methylation associated with acute lymphoblastic leukemia (ALL) and showed that selected molecular targets can be pharmacologically modulated to reverse gene silencing.
  • Next, the relationship between methylation and expression of these genes was examined in ALL cell lines (NALM-6 and Jurkat) before and after treatments with 5-aza-2-deoxycytidine and trichostatin A.
  • [MeSH-major] CpG Islands. DNA Methylation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Carrier Proteins / genetics. Gene Expression Regulation, Leukemic. Gene Silencing. Genes, Tumor Suppressor. Humans. Jurkat Cells. Nerve Tissue Proteins / genetics. Oligonucleotide Array Sequence Analysis. Physical Chromosome Mapping. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Promoter Regions, Genetic. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17363581.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA097880; United States / NCI NIH HHS / CA / CA100055; United States / NLM NIH HHS / LM / LM07089
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / RPIB9 protein, human
  •  go-up   go-down


91. Kobayashi T, Ohashi K, Sakai M, Yamashita T, Okuyama Y, Hiruma K, Akiyama H, Sakamaki H: Granulocyte colony-stimulating factor-primed donor lymphocyte infusion after salvage chemotherapy for treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Int J Hematol; 2005 Jul;82(1):79-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocyte colony-stimulating factor-primed donor lymphocyte infusion after salvage chemotherapy for treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / therapeutic use. Lymphocyte Transfusion. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):405-12 [11786567.001]
  • [Cites] Br J Haematol. 1988 Nov;70(3):317-20 [3061443.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] Hematology. 2001;6(4):261-5 [27414845.001]
  • [Cites] Bone Marrow Transplant. 1997 Oct;20(7):533-41 [9337054.001]
  • [Cites] Leukemia. 2001 Mar;15(3):355-61 [11237057.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1789-97 [15385924.001]
  • [Cites] Haematologica. 1999 Jun;84(6):505-10 [10366793.001]
  • [Cites] Haematologica. 1999 Mar;84(3):226-30 [10189387.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3603-12 [7949117.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(5):511-6 [11019840.001]
  • (PMID = 16105765.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD34; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


92. Jacobs JF, Brons PP, Simons A, van der Reijden BA, Hoogerbrugge PM: Therapy-related, donor-derived AML responding to a second allogeneic BMT. Bone Marrow Transplant; 2007 Sep;40(5):499-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Leukemia, Myeloid / etiology. Leukemia, Myeloid / therapy. Neoplasms, Second Primary / therapy
  • [MeSH-minor] Acute Disease. Cytogenetic Analysis. Gene Rearrangement. Humans. Infant. Male. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Tissue Donors. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17589531.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


93. Li YN, Zou DH, Gu M, Mi YC, Wang JX, Qiu LG: [The role of BCR/ABL isoforms in the presentations and outcome of Philadelphia-positive acute lymphoblastic leukemia in adult patients]. Zhonghua Nei Ke Za Zhi; 2009 Jun;48(6):481-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of BCR/ABL isoforms in the presentations and outcome of Philadelphia-positive acute lymphoblastic leukemia in adult patients].
  • OBJECTIVE: To investigate the difference of clinical characteristics and outcomes between different isoforms of BCR/ABL in adults with Philadelphia-positive acute lymphoblastic leukemia (ALL).
  • RESULTS: The median age of the 106 patients was 34 years and the median white blood cell count at baseline was 28.5 x 10(9)/L.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954044.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / abl-bcr fusion protein, human; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


94. Sasse EC, Sasse AD, Brandalise S, Clark OA, Richards S: Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev; 2005;(3):CD004139
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia.
  • BACKGROUND: Acute lymphoblastic leukaemia (ALL) is the most common cancer in childhood and febrile neutropenia is a potentially life-threatening side effect of its treatment.
  • [MeSH-major] Fever / prevention & control. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Macrophage Colony-Stimulating Factor / therapeutic use. Neutropenia / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Fever.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034921.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 81627-83-0 / Macrophage Colony-Stimulating Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Number-of-references] 76
  •  go-up   go-down


95. Aversa F: Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant; 2008 Mar;41(5):473-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States.
  • The graft may be a megadose of extensively T cell-depleted or unmanipulated progenitor cells.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


96. Verrills NM, Liem NL, Liaw TY, Hood BD, Lock RB, Kavallaris M: Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia--an in vivo study. Proteomics; 2006 Mar;6(5):1681-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia--an in vivo study.
  • Intrinsic or acquired resistance to vincristine (VCR), an antimicrotubule agent used in the treatment of childhood acute lymphoblastic leukemia (ALL), is a major clinical problem.
  • The actin-regulating protein gelsolin was increased in both acquired and resistant leukemia as confirmed by immunoblotting and gene expression.
  • The major cytoskeletal protein, gamma-actin, was down-regulated in the VCR-resistant leukemia xenografts; in contrast, there was no significant change in beta-actin expression.
  • This study provides the first evidence for a role of the actin cytoskeleton in intrinsic and acquired in vivo antimicrotubule drug resistance in childhood leukemia and highlights the power of 2-D DIGE for the discovery of resistance markers, pharmacoproteomics, and signaling pathways in cancer.
  • [MeSH-major] Actins / metabolism. Antineoplastic Agents, Phytogenic / therapeutic use. Cytoskeleton / metabolism. Drug Resistance, Neoplasm. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Proteome / analysis


97. Moorman AV, Richards SM, Robinson HM, Strefford JC, Gibson BE, Kinsey SE, Eden TO, Vora AJ, Mitchell CD, Harrison CJ, UK Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Childhood Leukaemia Working Party (CLWP): Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood; 2007 Mar 15;109(6):2327-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21).
  • Patients with acute lymphoblastic leukemia (ALL) and an intrachromosomal amplification of chromosome 21 (iAMP21) comprise a novel and distinct biological subgroup.
  • We prospectively screened 1630 (84%) patients treated on the UK MRC ALL97 protocol for iAMP21 and herein present demographic, clinical, and survival data on the 28 (2%) children found to harbor this abnormality.
  • They had a common or pre-B ALL immunophenotype, were significantly older (median 9 years vs 5 years), and had a lower white cell count (median 3.9 vs 12.4) compared with children without this abnormality.
  • [MeSH-major] Chromosomes, Human, Pair 21 / genetics. Gene Amplification / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17095619.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300130
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


98. Molina J, Molins T, Gil FJ, Sagaseta de Ilurdoz M, Ruipérez E, Guembero E, Sala F, Valiente A, Labaca MA: [Experience and results of acute lymphoblastic leukaemia treatment in children between 1989-2005 in Navarre]. An Sist Sanit Navar; 2007 Sep-Dec;30(3):363-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience and results of acute lymphoblastic leukaemia treatment in children between 1989-2005 in Navarre].
  • [Transliterated title] Experiencia y resultados en el tratamiento de la leucemia linfoblástica aguda en la edad pediátrica en el periodo comprendido entre 1989 y 2005 en la Comunidad de Navarra.
  • BACKGROUND: The determination of prognostic factors in acute lymphoblastic leukaemia (ALL) is increasingly important in establishing a correct treatment.
  • We analyse the overall survival (OS), event free survival (EFS) and prognostic factors in our 16 years experience of treating acute lymphoblastic leukaemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18227893.001).
  • [ISSN] 1137-6627
  • [Journal-full-title] Anales del sistema sanitario de Navarra
  • [ISO-abbreviation] An Sist Sanit Navar
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


99. Schechter T, Liebman M, Gassas A, Ngan BY, Navarro OM: BK virus-associated hemorrhagic cystitis presenting as mural nodules in the urinary bladder after hematopoietic stem cell transplantation. Pediatr Radiol; 2010 Aug;40(8):1430-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BK virus-associated hemorrhagic cystitis presenting as mural nodules in the urinary bladder after hematopoietic stem cell transplantation.
  • We report an unusual sonographic presentation of late-onset hemorrhagic cystitis caused by BK virus infection in an 8-year-old who had undergone hematopoietic stem cell transplantation for treatment of relapsed acute lymphoblastic leukemia.
  • [MeSH-major] BK Virus. Cystitis / complications. Hemorrhage / complications. Polyomavirus Infections / complications. Stem Cell Transplantation / adverse effects. Tumor Virus Infections / complications. Urinary Bladder / diagnostic imaging
  • [MeSH-minor] Child. Humans. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Recurrence. Ultrasonography

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1993 Nov;12 (5):463-7 [8298557.001]
  • [Cites] Pediatr Radiol. 2000 Mar;30(3):131-8 [10755748.001]
  • [Cites] J Clin Ultrasound. 1991 Jul-Aug;19(6):321-33 [1682346.001]
  • [Cites] J Clin Ultrasound. 1988 Mar-Apr;16(3):183-6 [3150400.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Oct;11(10):797-804 [16182180.001]
  • [Cites] Pediatr Hematol Oncol. 2002 Jun;19(4):255-61 [12051592.001]
  • [Cites] Bone Marrow Transplant. 2008 Jan;41(1):11-8 [17952131.001]
  • [Cites] Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S39-42 [18545243.001]
  • (PMID = 20221593.001).
  • [ISSN] 1432-1998
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


100. O'Brien MM, Lee-Kim Y, George TI, McClain KL, Twist CJ, Jeng M: Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer; 2008 Feb;50(2):381-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis.
  • Secondary HLH due to malignancy occurs most commonly with T or NK-cell lymphoid neoplasms.
  • HLH with B-cell malignancies is less common and HLH has rarely been described in association with precursor B-cell acute lymphoblastic leukemia (B-ALL).
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications






Advertisement